<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Combined oral contraceptive pill for primary dysmenorrhoea - Schroll, JB - 2023 | Cochrane Library</title> <meta content="Combined oral contraceptive pill for primary dysmenorrhoea - Schroll, JB - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002120.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Combined oral contraceptive pill for primary dysmenorrhoea - Schroll, JB - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002120.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD002120.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Combined oral contraceptive pill for primary dysmenorrhoea" name="citation_title"/> <meta content="Jeppe B Schroll" name="citation_author"/> <meta content="Copenhagen University Hospital Hvidovre" name="citation_author_institution"/> <meta content="jschroll@gmail.com" name="citation_author_email"/> <meta content="Amanda Y Black" name="citation_author"/> <meta content="University of Ottawa" name="citation_author_institution"/> <meta content="Cindy Farquhar" name="citation_author"/> <meta content="The University of Auckland" name="citation_author_institution"/> <meta content="Innie Chen" name="citation_author"/> <meta content="University of Ottawa" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD002120.pub4" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/07/31" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002120.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002120.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002120.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti-Inflammatory Agents, Non-Steroidal [adverse effects]; *Contraceptives, Oral, Combined [adverse effects]; *Dysmenorrhea [drug therapy]; Headache; Muscle Cramp" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002120.pub4&amp;doi=10.1002/14651858.CD002120.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002120.pub4&amp;doi=10.1002/14651858.CD002120.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002120.pub4&amp;doi=10.1002/14651858.CD002120.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002120.pub4&amp;doi=10.1002/14651858.CD002120.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002120.pub4&amp;doi=10.1002/14651858.CD002120.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002120.pub4&amp;doi=10.1002/14651858.CD002120.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002120.pub4&amp;doi=10.1002/14651858.CD002120.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002120.pub4&amp;doi=10.1002/14651858.CD002120.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002120.pub4&amp;doi=10.1002/14651858.CD002120.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002120.pub4&amp;doi=10.1002/14651858.CD002120.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002120.pub4&amp;doi=10.1002/14651858.CD002120.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002120.pub4&amp;doi=10.1002/14651858.CD002120.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002120.pub4&amp;doi=10.1002/14651858.CD002120.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002120.pub4&amp;doi=10.1002/14651858.CD002120.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002120.pub4&amp;doi=10.1002/14651858.CD002120.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002120.pub4&amp;doi=10.1002/14651858.CD002120.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002120.pub4&amp;doi=10.1002/14651858.CD002120.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002120.pub4&amp;doi=10.1002/14651858.CD002120.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002120.pub4&amp;doi=10.1002/14651858.CD002120.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002120.pub4&amp;doi=10.1002/14651858.CD002120.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002120.pub4&amp;doi=10.1002/14651858.CD002120.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002120.pub4&amp;doi=10.1002/14651858.CD002120.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002120.pub4&amp;doi=10.1002/14651858.CD002120.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="qy4lqFNF";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD002120\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD002120\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002120\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002120\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","ko","pt","ms","hr","fr","zh_HANT","th","ja","fa","pl","ro"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD002120.pub4",title:"Combined oral contraceptive pill for primary dysmenorrhoea",firstPublishedDate:"Jul 31, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecology and Fertility Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=qy4lqFNF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002120.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002120.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD002120.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD002120.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002120.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD002120.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ro&quot;,&quot;title&quot;:&quot;Sumar&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD002120.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD002120.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD002120.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD002120.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4063 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD002120.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002120.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002120.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002120.pub4/full#CD002120-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002120.pub4/full#CD002120-sec-0111"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002120.pub4/full#CD002120-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002120.pub4/full#CD002120-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002120.pub4/full#CD002120-sec-0016"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002120.pub4/full#CD002120-sec-0017"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002120.pub4/full#CD002120-sec-0043"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002120.pub4/full#CD002120-sec-0105"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002120.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002120.pub4/appendices#CD002120-sec-0116"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002120.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002120.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/supinfo/CD002120-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/supinfo/CD002120-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002120.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002120.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002120.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002120.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002120.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD002120.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Combined oral contraceptive pill for primary dysmenorrhoea</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002120.pub4/information#CD002120-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Jeppe B Schroll</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002120.pub4/information#CD002120-cr-0005">Amanda Y Black</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002120.pub4/information#CD002120-cr-0006">Cindy Farquhar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002120.pub4/information#CD002120-cr-0007">Innie Chen</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/information/en#CD002120-sec-0127">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 31 July 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD002120.pub4">https://doi.org/10.1002/14651858.CD002120.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD002120-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002120-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002120-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002120-abs-0018">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002120-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD002120-abs-0005">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD002120-abs-0015">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD002120-abs-0001" lang="en"> <section id="CD002120-sec-0001"> <h3 class="title" id="CD002120-sec-0001">Background</h3> <p>Dysmenorrhoea (painful menstrual cramps) is common and a major cause of pain in women. Combined oral contraceptives (OCPs) are often used in the management of primary dysmenorrhoea, but there is a need for reporting the benefits and harms. Primary dysmenorrhoea is defined as painful menstrual cramps without pelvic pathology. </p> </section> <section id="CD002120-sec-0002"> <h3 class="title" id="CD002120-sec-0002">Objectives</h3> <p>To evaluate the benefits and harms of combined oral contraceptive pills for the management of primary dysmenorrhoea. </p> </section> <section id="CD002120-sec-0003"> <h3 class="title" id="CD002120-sec-0003">Search methods</h3> <p>We used standard, extensive Cochrane search methods. The latest search date 28 March 2023. </p> </section> <section id="CD002120-sec-0004"> <h3 class="title" id="CD002120-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) comparing all combined OCPs with other combined OCPs, placebo, or management with non‐steroidal anti‐inflammatory drugs (NSAIDs). Participants had to have primary dysmenorrhoea, diagnosed by ruling out pelvic pathology through pelvic examination or ultrasound. </p> </section> <section id="CD002120-sec-0005"> <h3 class="title" id="CD002120-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures recommended by Cochrane. The primary outcomes were pain score after treatment, improvement in pain, and adverse events. </p> </section> <section id="CD002120-sec-0006"> <h3 class="title" id="CD002120-sec-0006">Main results</h3> <p>We included 21 RCTs (3723 women). Eleven RCTs compared combined OCP with placebo, eight compared different dosages of combined OCP, one compared two OCP regimens with placebo, and one compared OCP with NSAIDs. </p> <p><b>OCP versus placebo or no treatment</b> </p> <p>OCPs reduce pain in women with dysmenorrhoea more effectively than placebo. Six studies reported treatment effects on different scales; the result can be interpreted as a moderate reduction in pain (standardised mean difference (SMD) −0.58, 95% confidence interval (CI) −0.74 to −0.41; I² = 28%; 6 RCTs, 588 women; high‐quality evidence). Six studies also reported pain improvement as a dichotomous outcome (risk ratio (RR) 1.65, 95% CI 1.29 to 2.10; I² = 69%; 6 RCTs, 717 women; low‐quality evidence). The data suggest that in women with a 28% chance of improvement in pain with placebo or no treatment, the improvement in women using combined OCP will be between 37% and 60%. </p> <p>Compared to placebo or no treatment, OCPs probably increase the risk of any adverse events (RR 1.31, 95% CI 1.20 to 1.43; I² = 79%; 7 RCTs, 1025 women; moderate‐quality evidence), and may also increase the risk of serious adverse events (RR 1.77, 95% CI 0.49 to 6.43; I² = 22%; 4 RCTs, 512 women; low‐quality evidence). </p> <p>Women who received OCPs had an increased risk of irregular bleeding compared to women who received placebo or no treatment (RR 2.63, 95% CI 2.11 to 3.28; I² = 29%; 7 RCTs, 1025 women; high‐quality evidence). In women with a risk of irregular bleeding of 18% if using placebo or no treatment, the risk would be between 39% and 60% if using combined OCP. OCPs probably increase the risk of headaches (RR 1.51, 95% CI 1.11 to 2.04; I² = 44%; 5 RCTs, 656 women; moderate‐quality evidence), and nausea (RR 1.64, 95% CI 1.17 to 2.30; I² = 39%; 8 RCTs, 948 women; moderate‐quality evidence). We are uncertain of the effect of OCP on weight gain (RR 1.83, 95% CI 0.75 to 4.45; 1 RCT, 76 women; low‐quality evidence). OCPs may slightly reduce requirements for additional medication (RR 0.63, 95% CI 0.40 to 0.98; I² = 0%; 2 RCTs, 163 women; low‐quality evidence), and absence from work (RR 0.63, 95% CI 0.41 to 0.97; I² = 0%; 2 RCTs, 148 women; low‐quality evidence). </p> <p><b>One OCP versus another OCP</b> </p> <p>Continuous use of OCPs (no pause or inactive tablets after the usual 21 days of hormone pills) may reduce pain in women with dysmenorrhoea more effectively than the standard regimen (SMD −0.73, 95% CI −1.13 to 0.34; 2 RCTs, 106 women; low‐quality evidence). There was insufficient evidence to determine if there was a difference in pain improvement between ethinylestradiol 20 μg and ethinylestradiol 30 μg OCPs (RR 1.06, 95% CI 0.65 to 1.74; 1 RCT, 326 women; moderate‐quality evidence). There is probably little or no difference between third‐ and fourth‐generation and first‐ and second‐generation OCPs (RR 0.99, 95% CI 0.93 to 1.05; 1 RCT, 178 women; moderate‐quality evidence). The standard regimen of OCPs may slightly increase the risk of any adverse events over the continuous regimen (RR 1.11, 95% CI 1.01 to 1.22; I² = 76%; 3 RCTs, 602 women; low‐quality evidence), and probably increases the risk of irregular bleeding (RR 1.38, 95% CI 1.14 to 1.69; 2 RCTs, 379 women; moderate‐quality evidence). Due to lack of studies, it is uncertain if there is a difference between continuous and standard regimen OCPs in serious adverse events (RR 0.34, 95% CI 0.01 to 8.24; 1 RCT, 212 women), headaches (RR 0.94, 95% CI 0.50 to 1.76; I² = 0%; 2 RCTs, 435 women), or nausea (RR 1.08, 95% CI 0.51 to 2.30; I² = 23%; 2 RCTs, 435 women) (all very low‐quality evidence). </p> <p>We are uncertain if one type of OCP reduces absence from work more than the other (RR 1.12, 95% CI 0.64 to 1.99; 1 RCT, 445 women; very low‐quality evidence). </p> <p><b>OCPs versus NSAIDs</b> </p> <p>There were insufficient data to determine whether OCPs were more effective than NSAIDs for pain (mean difference −0.30, 95% CI −5.43 to 4.83; 1 RCT, 91 women; low‐quality evidence). The study did not report on adverse events. </p> </section> <section id="CD002120-sec-0007"> <h3 class="title" id="CD002120-sec-0007">Authors' conclusions</h3> <p>OCPs are effective for treating dysmenorrhoea, but they cause irregular bleeding, and probably headache and nausea. Long‐term effects were not covered in this review. Continuous use of OCPs was probably more effective than the standard regimen but safety should be ensured with long‐term data. Due to lack of data, we are uncertain whether NSAIDs are better than OCPs for treating dysmenorrhoea. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD002120-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002120-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD002120-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD002120-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002120-abs-0019">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002120-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD002120-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD002120-abs-0017">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD002120-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD002120-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD002120-abs-0020">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD002120-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/ro#CD002120-abs-0021">Română</a> </li> <li class="section-language"> <a class="" href="full/ru#CD002120-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD002120-abs-0016">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD002120-abs-0014">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD002120-abs-0002" lang="en"> <h3>Combined oral contraceptive pill (OCP) as treatment for primary dysmenorrhoea</h3> <p><b>Review question</b> </p> <p>Cochrane authors reviewed the evidence on the effectiveness and safety of combined oral contraceptive pills (OCPs) for the treatment of painful menstrual cramps (period pains, also called dysmenorrhoea). </p> <p><b>Background</b> </p> <p>OCPs are readily used as a treatment for menstrual cramps, but the evidence was uncertain about the effects. </p> <p><b>Study characteristics</b> </p> <p>We found 21 randomised controlled trials (clinical studies where people are randomly put into one of two or more treatment groups) that compared the effects of OCPs with either placebo (fake pill), other OCPs, or non‐steroidal anti‐inflammatory medicines that reduce pain and inflammation. The studies included 3723 women. Most women had painful menstrual cramps of at least moderate severity. Manufacturers of OCPs funded 11 studies. We searched the databases in March 2023. </p> <p><b>Key results</b> </p> <p><b><i>OCPs compared to placebo</i> </b> </p> <p>OCPs reduce pain by 0.7 to 1.3 points more on the total dysmenorrhoea scale (range 0 to 6) than placebo in women with menstrual cramps (6 studies with 588 women; high‐quality evidence). The six studies that measured improvement as a yes/no category showed that OCPs may reduce pain. Women with a 28% chance of improving on placebo may have a 37% to 60% chance of improving on OCPs (low‐quality evidence). </p> <p>OCPs increase the risk of side effects (59% in placebo group compared to 71% to 86% in OCP group; moderate‐quality evidence), and may lead to more serious side effects (1.1% in placebo group compared to 0.5% to 6.8% in OCP group; low‐quality evidence). </p> <p>Irregular bleeding increases among women using OCPs. Women with an 18% risk of irregular bleeding on placebo have a 39% to 60% risk of irregular bleeding on OCPs (high‐quality evidence). Moderate‐quality evidence found that OCPs probably increase the risk of headaches (17% in placebo group compared to 19% to 35% in OCP group), and nausea (feeling sick; 10% in placebo group compared to 11% to 22% in OCP group). </p> <p>We are uncertain of the effect of OCP on weight gain.</p> <p>Low‐quality evidence found that OCPs may slightly reduce the need for extra medicine (38% in placebo group compared to 15% to 37% in OCP group), and absence from work (36% in placebo group compared to 11% to 35% in OCP group). </p> <p><b><i>Different OCPs compared to each other</i> </b> </p> <p>There may be little or no difference between OCPs that contain low or high doses of oestrogen, or between newer and older formulations of OCPs (moderate‐quality evidence). </p> <p>Using continuous OCP (no inactive pills taken as a break between active pills, to postpone bleeding) might reduce pain more than the traditional regimen (low‐quality evidence). The traditional regimen is to take active tablets for 21 days and pausing for 7 days (or taking inactive tables for 7 days) where a breakthrough bleeding will usually occur. </p> <p>There might be little or no difference in the risk of any side effects between the continuous and traditional regimens (65% in traditional group compared to 66% to 80% in continuous group; low‐quality evidence). </p> <p>Due to very low‐quality evidence, we are uncertain if there is a difference in the risk of serious side effects (0.9% in traditional group compared to 0.3% to 7.7% in continuous group), headaches (8% in traditional group compared to 4% to 15% in continuous group), nausea (6% in traditional group compared to 3% to 13% in continuous group) or absence from work (9% in traditional group compared to 6% to 18% in continuous group). Continuous use of OCP probably increases irregular bleeding (33% in traditional group compared to 38% to 56% in continuous group; moderate‐quality evidence). </p> <p>These studies did not report on weight gain or the need for extra medicine.</p> <p><b><i>OCP compared to a non‐steroidal anti‐inflammatory medicine</i> </b> </p> <p>Due to low‐quality evidence, we were unable to determine whether OCPs were more effective than non‐steroidal anti‐inflammatory medicines. Side effects were not reported. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of the evidence ranged from very low to high. The most important problems were a lack of data and variations in data between studies. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD002120-sec-0111" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD002120-sec-0111"></div> <h3 class="title" id="CD002120-sec-0112">Implications for practice</h3> <section id="CD002120-sec-0112"> <p>Oral contraceptive pills (OCPs) are effective at treating dysmenorrhoea, but they cause adverse events in the form of irregular bleeding, and probably headache and nausea. This review did not cover long‐term effects. </p> <p>Continuous use of OCPs may be more effective than the standard regimen, but safety should be ensured with long‐term data. Due to lack of data, we are uncertain whether non‐steroidal anti‐inflammatory drugs are better than OCPs at treating dysmenorrhoea. </p> </section> <h3 class="title" id="CD002120-sec-0113">Implications for research</h3> <section id="CD002120-sec-0113"> <p>No more studies comparing OCPs to placebo for dysmenorrhoea are needed.</p> <p>Long‐term studies ensuring the safety of continuous usage of OCP (i.e. without a pause after 21 days of hormone treatment) are needed; weight gain and irregular bleeding should be a focus. </p> <p>Comparisons with other standard medical treatments, such as non‐steroidal anti‐inflammatory drugs, would also be useful. </p> <p>Any future trials would need to be double‐blind, randomised controlled trials with adequate sample sizes, and use pain outcome measures, such as the Visual Analogue Scale, Total Dysmenorrhoea Score, or the Moos Menstrual Distress Questionnaire. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD002120-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD002120-sec-0008"></div> <div class="table" id="CD002120-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Combined OCP compared to placebo or no treatment for primary dysmenorrhoea</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Combined OCP compared to placebo or no treatment for primary dysmenorrhoea</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with primary dysmenorrhoea<br/><b>Setting:</b> medical centres and clinics<br/><b>Intervention:</b> combined OCP<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Quality</b> of the evidence<br/>(GRADE) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with combined OCP</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Pain score</b> </p> <p>(assessed with Total Dysmenorrhoea Score; 0–6; lower score is better; and Moos Menstrual Distress Questionnaire pain subscale; 0–24; lower score is better) </p> <p><i>follow‐up range 3–4 months</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The standardised mean pain score was <b>0.58 points lower</b><br/>(0.74 lower to 0.41 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>588<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The change in standardised mean difference represents an improvement of 0.8 point on the Total Dysmenorrhoea Score (0–6) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Pain improvement</b> </p> <p>(assessed as improvement from 1 major category to next)</p> <p><i>follow‐up range 1–4 months</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>284 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>469 per 1000<br/>(367 to 597) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.65</b><br/>(1.29 to 2.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>717<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>590 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>773 per 1000<br/>(708 to 855) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.31</b><br/>(1.20 to 1.43) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1025<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> <p><i>follow‐up range 3–4 months</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000<br/>(5 to 68) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.77</b><br/>(0.49 to 6.43) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>512<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Irregular bleeding</b> </p> <p><i>follow‐up range 3–4 months</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>182 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>479 per 1000<br/>(385 to 598) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.63</b><br/>(2.11 to 3.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1025<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Headaches</b> </p> <p><i>follow‐up range 3–4 months</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>174 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>262 per 1000<br/>(193 to 354) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.51</b><br/>(1.11 to 2.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>656<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Nausea</b> </p> <p><i>follow‐up range 3–4 months</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>95 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>156 per 1000<br/>(111 to 219) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.64</b><br/>(1.17 to 2.30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>948<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weight gain</b> </p> <p><i>3‐month follow‐up</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>158 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>289 per 1000<br/>(118 to 703) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.83</b><br/>(0.75 to 4.45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Requirement for additional medication</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>377 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>237 per 1000<br/>(151 to 369) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.63</b><br/>(0.40 to 0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>f,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Absence from work or school</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>362 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>228 per 1000<br/>(112 to 351) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.63</b><br/>(0.41 to 0.97) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>f,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>OCP:</b> oral contraceptive pill; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Most studies sponsored by industry, but other risk of bias domains were mostly low, so overall, this was considered not serious.<br/><sup>b</sup>The I² was 45%, but we did not downgrade.<br/><sup>c</sup>Downgraded one level for inconsistency – I² above 50%.<br/><sup>d</sup>Downgraded one level for indirectness – 5 studies from the 1960/1970s that used drugs that are not available today. The reports contained very little information on risk of bias; combined with some imprecision, we decided to downgrade one level.<br/><sup>e</sup>Downgraded two levels for imprecision – wide confidence intervals.<br/><sup>f</sup>Downgraded one level due to some imprecision and some heterogeneity.<br/><sup>g</sup>Downgraded one level due to imprecision and few events.<br/><sup>h</sup>Downgraded one level due to risk of bias and concerns of indirectness. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002120-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Combined low‐dose OCP compared to another combined low‐dose OCP for primary dysmenorrhoea</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Combined low‐dose OCP compared to another combined low‐dose OCP for primary dysmenorrhoea</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with primary dysmenorrhoea<br/><b>Setting:</b> medical centres and clinics<br/><b>Intervention:</b> combined low‐dose OCP<br/><b>Comparison:</b> different combined low‐dose OCP </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Quality</b> of the evidence<br/>(GRADE) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with standard combined‐low‐dose OCP</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with experimental combined low‐dose OCP</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Pain score</b> </p> <p>(assessed with VAS; 0 to 100; lower score is better)</p> <p><i>follow‐up range 4–6 months</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The standardised mean pain score in the continuous regimen group was <b>0.73 points lower</b><br/>(1.13 lower to 0.34 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The change in SMD represented an improvement of 4 to 18 point on a VAS scale (0–100)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pain improvement</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EE 20 μg vs EE 30 μg</p> <p><i>6‐month follow‐up</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>259 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>275 per 1000<br/>(169 to 251) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.06</b><br/>(0.65 to 1.74) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>326<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4th/3rd vs 1st/2nd generation</p> <p><i>6‐month follow‐up</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>966 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>957 per 1000<br/>(899 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.99</b><br/>(0.93 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse events</b> for continuous vs standard regimen OCP </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adverse events</b> </p> <p><i>follow‐up range 4–6 months</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>652 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>724 per 1000<br/>(659 to 795) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.11</b><br/>(1.01 to 1.22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>602<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> <p><i>6‐month follow‐up</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000<br/>(0 to 77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.34</b><br/>(0.01 to 8.24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>212<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Irregular bleeding</b> </p> <p><i>follow‐up range 4–6 months</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>330 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>455 per 1000<br/>(376 to 557) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.38</b><br/>(1.14 to 1.69) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>379<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Headaches</b> </p> <p><i>follow‐up range 4–6 months</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>84 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>79 per 1000<br/>(42 to 147) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b><br/>(0.50 to 1.76) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>435<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nausea</b><br/><i>follow‐up range 4–6 months</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 per 1000<br/>(28 to 128) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b><br/>(0.51 to 2.30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>435<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study assessed vomiting, which we interpreted as a proxy for nausea.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Weight gain</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported in any study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Requirement for additional medication</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported in any study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Absence from work or school</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>91 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>102 per 1000<br/>(58 to 181) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b><br/>(0.64 to 1.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>445<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>EE:</b> ethinylestradiol; <b>OCP:</b> oral contraceptive pill; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference; <b>VAS:</b> Visual Analogue Scale. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for risk of bias – studies not blinded, which is also difficult as vaginal bleeding should lead to pause in the continuous group<br/><sup>b</sup>Downgraded one level for imprecision – wide confidence intervals or few included participants<br/><sup>c</sup>Downgraded one level for heterogeneity – I² above 50%<br/><sup>d</sup>Downgraded two levels for imprecision – wide confidence intervals </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002120-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">NSAID compared to combined OCP for primary dysmenorrhoea</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>NSAID compared to combined OCP for primary dysmenorrhoea</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with primary dysmenorrhoea<br/><b>Setting:</b> medical centre<br/><b>Intervention:</b> NSAID<br/><b>Comparison:</b> combined OCP </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Quality</b> of the evidence<br/>(GRADE) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with combined OCP</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with NSAIDs</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Pain score</b> </p> <p>(measured on VAS; 0–100; lower score is better)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain score in the combined OCP group was 35</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain score in the NSAID group was 0.30 points lower (5.43 lower to 4.83 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Pain improvement</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported in any study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported in any study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported in any study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Irregular bleeding</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported in any study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Headaches</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported in any study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nausea</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported in any study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weight gain</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported in any study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Requirement for additional medication</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported in any study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Absence from work or school</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported in any study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>NSAID:</b> non‐steroidal anti‐inflammatory drug; <b>OCP:</b> oral contraceptive pill; <b>RCT:</b> randomised controlled trial; <b>VAS:</b> Visual Analogue Scale. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for imprecision – wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD002120-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD002120-sec-0009"></div> <section id="CD002120-sec-0010"> <h3 class="title" id="CD002120-sec-0010">Description of the condition</h3> <p>Dysmenorrhoea is painful menstrual cramps. It is a common gynaecological problem that affect as many as 50% to 60% of women; around 15% of these women experience enough pain to temporarily render them incapacitated, which results in absences from work or school (<a href="./references#CD002120-bbs2-0043" title="BurnettMA , AntaoV , BlackA , FeldmanK , GrenvilleA , LeaR , et al. Prevalence of primary dysmenorrhea in Canada. Journal of Obstetrics and Gynaecology Canada2005;27(8):765-70.">Burnett 2005</a>; <a href="./references#CD002120-bbs2-0046" title="DawoodMY . Primary dysmenorrhea – advances in pathogenesis and management. Obstetrics and Gynecology2006;108(2):428-41.">Dawood 2006</a>; <a href="./references#CD002120-bbs2-0051" title="JuH , JonesM , MishraG . The prevalence and risk factors of dysmenorrhea. Epidemiologic Reviews2014;36(1):104-13. [DOI: 10.1093/epirev/mxt009]">Ju 2014</a>). The impacts are significant, both in terms of quality of life and loss of earnings. </p> <p>Dysmenorrhoea is commonly subcategorised into primary and secondary dysmenorrhoea. Menstrual pain without organic pathology is considered to be primary dysmenorrhoea (<a href="./references#CD002120-bbs2-0044" title="CocoAS . Primary dysmenorrhoea. American Family Physician1999;60(2):489-96.">Coco 1999</a>). When the pelvic pain is associated with an identifiable pathological condition, such as endometriosis or ovarian cysts, it is considered to be secondary dysmenorrhoea. </p> <p>The initial onset of primary dysmenorrhoea is usually at, or shortly after, menarche (within 6 to 12 months), when ovulatory cycles are established. The pain duration commonly ranges from 8 to 72 hours, and is associated with menstrual flow. In contrast, secondary dysmenorrhoea is more likely to develop years after the onset of menarche, and occur premenstrually, as well as during menstruation. </p> <section id="CD002120-sec-0011"> <h4 class="title">Aetiology of the conditions</h4> <p>The aetiology (cause) of primary dysmenorrhoea has been the subject of considerable debate. Experimental and clinical research has identified the over‐production or imbalanced levels of uterine prostaglandins as a substantial contributing factor to the painful cramps that are the major symptom of dysmenorrhoea (<a href="./references#CD002120-bbs2-0046" title="DawoodMY . Primary dysmenorrhea – advances in pathogenesis and management. Obstetrics and Gynecology2006;108(2):428-41.">Dawood 2006</a>). Prostaglandin production is controlled by progesterone; immediately prior to menstruation, progesterone levels drop, causing prostaglandin production to increase. If these prostaglandins are overproduced, cramping can occur. The process of ovulation is also implicated; dysmenorrhoea mostly only occurs in ovulatory cycles, which helps explain why the initial onset of primary dysmenorrhoea occurs shortly after menarche, when ovulatory cycles become established (<a href="./references#CD002120-bbs2-0045" title="DawoodMY . Dysmenorrhea. Clinical Obstetrics and Gynecology1990;33(1):168-78.">Dawood 1990</a>). </p> </section> </section> <section id="CD002120-sec-0012"> <h3 class="title" id="CD002120-sec-0012">Description of the intervention</h3> <p>As early as 1937, research has shown that dysmenorrhoea responds favourably to ovulation inhibition, and that the synthetic hormones in the combined oral contraceptive pill (OCP) can be used to manage dysmenorrhoea (<a href="./references#CD002120-bbs2-0052" title="KarnakyKJ . Development of the oral contraceptives. American Journal of Obstetrics and Gynecology1975;123(7):771-2.">Karnaky 1975</a>). These hormones act by suppressing ovulation and lessening the endometrial lining of the uterus. Therefore, menstrual fluid volume decreases, along with the level of prostaglandins produced, which then reduces dysmenorrhoea by decreasing uterine motility and uterine cramping. </p> <p>The use of combined OCPs has been advocated as a treatment for primary dysmenorrhoea since their introduction for general use in 1960. OCP use for secondary dysmenorrhoea has also been questioned; although this type of treatment may have some favourable effect on dysmenorrhoea, ultimately, the organic cause of the pain must be addressed (<a href="./references#CD002120-bbs2-0042" title="Committee on Adolescent Health Care. ACOG Committee opinion No. 760. Dysmenorrhea and endometriosis in the adolescent. Obstetrics and Gynecology2018;132(6):e249-58. [DOI: 10.1097/AOG.0000000000002978]">ACOG 2018</a>). </p> <p>Progestogens are traditionally categorised into first, second, third, and fourth generation, based on when they were synthesised (<a href="./references#CD002120-bbs2-0059" title="RegidorP . The clinical relevance of progestogens in hormonal contraception: present status and future developments. Oncotarget2018;77:34628-38.">Regidor 2018</a>). The categories might share some biochemical, as well as clinical features, even though the traditional categories are being challenged. </p> <section id="CD002120-sec-0013"> <h4 class="title">Adverse effects of intervention</h4> <p>One potential drawback of the use of OCPs is the possible adverse effects that can accompany the two hormones used. Oestrogen‐related adverse effects may include nausea, vomiting, headaches, breast tenderness, and changes in bodyweight; progesterone‐related adverse effects may include acne, weight gain, increased hair growth, and depression. Citing a cause‐and‐effect relationship between OCPs and these adverse effects may be misleading, as they are also observed in women with dysmenorrhoea. </p> <p>Potentially serious, but rare, adverse effects of oestrogens are deep venous thrombosis (blood clotting in the veins) (<a href="./references#CD002120-bbs2-0053" title="LidegaardO , NielsenLH , SkovlundCW , LøkkegaardE . Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10. BMJ2012;344:e2990.">Lidegaard 2012a</a>), arterial disease, such as myocardial infarctions and stroke (<a href="./references#CD002120-bbs2-0054" title="Lidegaard Ø, LøkkegaardE , JensenA , SkovlundCW , KeidingN . Thrombotic stroke and myocardial infarction with hormonal contraception. New England Journal of Medicine2012;366(24):2257-66.">Lidegaard 2012b</a>), breast cancer (<a href="./references#CD002120-bbs2-0058" title="MørchLS , HannafordPC , Lidegaard Ø. Contemporary hormonal contraception and the risk of breast cancer. New England Journal of Medicine2017;377(23):2228-39. [DOI: 10.1056/NEJMoa1700732]">Mørch 2017</a>), and depression (<a href="./references#CD002120-bbs2-0063" title="SkovlundCW , MørchLS , KessingLV , Lidegaard Ø. Association of hormonal contraception with depression. JAMA Psychiatry2016;73:1154-62.">Skovlund 2016</a>). Lower‐dose OCPs have been developed to lessen any potential adverse effects. In contrast to older OCPs, which contain 50 μg to 150 μg of oestrogen, modern pills contain a low dose (less than 35 μg). The level of progestogen has also decreased with the move from first‐ or second‐generation progestogens (such as norgestrel, levonorgestrel, norethisterone) to third‐ and fourth‐generation progestogens (such as desogestrel, gestodene, drospirenone), which are more selective and have different effects on metabolic parameters. Therefore, combined OCPs can be categorised according to the level of oestrogen and the type of progestogen they contain. </p> </section> </section> <section id="CD002120-sec-0014"> <h3 class="title" id="CD002120-sec-0014">How the intervention might work</h3> <p>OCPs reduce the amount of endometrial tissue by inhibiting the buildup during the normal menstrual cycle. Prostaglandins and leukotrienes produced in the endometrium are responsible for uterine contractions, and are abundant in women reporting dysmenorrhoea (<a href="./references#CD002120-bbs2-0048" title="HarelZ . Dysmenorrhea in adolescents and young adults: from pathophysiology to pharmacological treatments and management strategies. Expert Opinion on Pharmacotherapy2008;9:2661-72.">Harel 2008</a>). Women using OCPs produce less prostaglandin due to the decreased amount of tissue, which leads to less intrauterine pressure and less pain (<a href="./references#CD002120-bbs2-0048" title="HarelZ . Dysmenorrhea in adolescents and young adults: from pathophysiology to pharmacological treatments and management strategies. Expert Opinion on Pharmacotherapy2008;9:2661-72.">Harel 2008</a>). Inhibition of ovulation may also limit the amount of prostaglandins produced. </p> </section> <section id="CD002120-sec-0015"> <h3 class="title" id="CD002120-sec-0015">Why it is important to do this review</h3> <p>Although combined OCPs have long been promoted as the management for primary dysmenorrhoea, very few trials have been conducted to study the efficacy and associated adverse events of their use. In addition, most of these trials are of poor methodological quality, which exposes them to a variety of biases. This is important to recognise in this review. </p> <p>Dysmenorrhoea is a debilitating gynaecological condition that impacts significantly on women around the world. Not only does it cause a decrease in personal health, but having to take time off work or school also results in loss of productivity, eventually leading to economic loss. Therefore, proper management of dysmenorrhoea will benefit individuals and society. </p> <p>There has also been debate around the adverse events of OCPs, and whether they were worth the benefits in managing dysmenorrhoea. Therefore, this review aimed to establish the usefulness of OCPs in managing dysmenorrhoea in the general female population, by comparing all relevant randomised controlled trials (RCTs). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD002120-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD002120-sec-0016"></div> <p>To evaluate the benefits and harms of combined oral contraceptive pills for the management of primary dysmenorrhoea. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD002120-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD002120-sec-0017"></div> <section id="CD002120-sec-0018"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD002120-sec-0019"> <h4 class="title">Types of studies</h4> <p>Published and unpublished RCTs that compared all types of combined OCP (oestrogen/progestogen) with placebo, no treatment, other combined OCPs, or non‐steroidal anti‐inflammatory drugs (NSAIDs) in the treatment of primary dysmenorrhoea. We only included cross‐over trials if pre‐ and post‐cross‐over data were available, and there was a washout period of two cycles. </p> </section> <section id="CD002120-sec-0020"> <h4 class="title">Types of participants</h4> <section id="CD002120-sec-0021"> <h5 class="title">Inclusion criteria</h5> <p>Women had to meet the following criteria for the trial to be included in the review.</p> <p> <ol id="CD002120-list-0001"> <li> <p>Of reproductive age.</p> </li> <li> <p>With primary dysmenorrhoea (moderate/severe pain for at least one day of menses). We would only include trials in which the severity of dysmenorrhoea was not formally assessed if the potential participants had sought medical advice for perceived pain. </p> </li> <li> <p>Lack of obvious pelvic pathology, diagnosed with a physical examination.</p> </li> <li> <p>Dysmenorrhoea in the majority of menstrual cycles.</p> </li> <li> <p>Regular ovulatory menstrual cycles (21‐ to 35‐day cycle).</p> </li> </ol> </p> </section> <section id="CD002120-sec-0022"> <h5 class="title">Exclusion criteria</h5> <p>If more than 20% of women met either of the following criteria, we did not include the trial in the review. </p> <p> <ol id="CD002120-list-0002"> <li> <p>Identifiable pelvic pathology (secondary dysmenorrhoea) or dysmenorrhoea from intrauterine device use. </p> </li> <li> <p>Infrequent dysmenorrhoea.</p> </li> </ol> </p> </section> </section> <section id="CD002120-sec-0023"> <h4 class="title">Types of interventions</h4> <p>We included trials that compared combined OCPs versus placebo, no treatment, other combined OCPs, and NSAIDs. </p> <p>The types of interventions were analysed according to the level and type of hormones used in the OCP. </p> <p> <ol id="CD002120-list-0003"> <li> <p>Combined OCP compared with placebo or no treatment</p> </li> <li> <p>OCP compared with another OCP</p> </li> <li> <p>OCP compared with NSAIDs</p> </li> </ol> </p> <p>For these comparisons, we stratified interventions according to the type of OCP.</p> <p> <ol id="CD002120-list-0004"> <li> <p>Low oestrogen (35 μg or less of oestrogen) and first/second‐generation progestogen</p> </li> <li> <p>Low oestrogen (35 μg or less of oestrogen) and third‐generation progestogen</p> </li> <li> <p>Moderate oestrogen (greater than 35 μg to less than 100 μg) and first/second‐generation progestogen </p> </li> </ol> </p> <p>OCPs containing 100 μg or more of oestrogen have been discontinued due to the increased risk of adverse effects associated with high levels of oestrogen, and we excluded them from this review. </p> <p>We included the following progestogens in the review.</p> <p> <ol id="CD002120-list-0005"> <li> <p>First‐ and second‐generation progestogens: norgestrel, levonorgestrel, levonorgestrel, and norethisterone </p> </li> <li> <p>Third‐generation progestogens: desogestrel and gestodene</p> </li> <li> <p>Fourth‐generation progestogens: dienogest and drospirenone</p> </li> </ol> </p> </section> <section id="CD002120-sec-0024"> <h4 class="title">Types of outcome measures</h4> <section id="CD002120-sec-0025"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD002120-list-0006"> <li> <p>Difference in pain between the treatment and control groups, measured with Visual Analogue Scale (VAS) or another scale, preferably at the end of treatment (continuous data). </p> </li> <li> <p>Difference in the number of women experiencing pain relief between the treatment and control groups at the end of treatment (dichotomous data). </p> </li> <li> <p>Adverse events from treatment (incidence and type of adverse events).</p> </li> </ol> </p> </section> <section id="CD002120-sec-0026"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD002120-list-0007"> <li> <p>Requirements for additional medication, measured as the number of women requiring analgesics in addition to their assigned treatment. </p> </li> <li> <p>Absence from work or school, measured as the ratio of women reporting absences from work or school, and as the number of hours or days of absence. </p> </li> <li> <p>Withdrawals from treatment.</p> </li> <li> <p>Withdrawal due to adverse events.</p> </li> </ol> </p> </section> </section> </section> <section id="CD002120-sec-0027"> <h3 class="title">Search methods for identification of studies</h3> <p>We sought all reports that described (or might have described) RCTs of combined OCPs in the treatment of primary dysmenorrhoea. The search strategies were developed in consultation with the Information Specialist from the Cochrane Gynaecology and Fertility Group. We did not restrict the search by language or date. </p> <section id="CD002120-sec-0028"> <h4 class="title">Electronic searches</h4> <p>The original search was undertaken in 2001. Updated searches were completed in February 2012, December 2018, May 2021, and March 2023. Search strategies were revised and redeveloped for the 2023 update of the review. See the previous versions of the review for details on old search strategies. </p> <p>We undertook electronic searches of:</p> <p> <ol id="CD002120-list-0008"> <li> <p>Cochrane Gynaecology and Fertility Group (CGF) Specialised Register of controlled trials, ProCite platform, searched 28 March 2023 (<a href="./appendices#CD002120-sec-0117">Appendix 1</a>); </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL), via the Cochrane Register of Studies Online (CRSO), Web platform, searched 28 March 2023 (<a href="./appendices#CD002120-sec-0118">Appendix 2</a>); </p> </li> <li> <p>MEDLINE, Ovid platform, searched from 1946 to 28 March 2023 (<a href="./appendices#CD002120-sec-0119">Appendix 3</a>); </p> </li> <li> <p>Embase, Ovid platform, searched from 1980 to 28 March 2023 (<a href="./appendices#CD002120-sec-0120">Appendix 4</a>); </p> </li> <li> <p>PsycINFO, Ovid platform searched from 1806 to 28 March 2023 (<a href="./appendices#CD002120-sec-0121">Appendix 5</a>). </p> </li> </ol> </p> </section> <section id="CD002120-sec-0029"> <h4 class="title">Searching other resources</h4> <p>We searched <a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a> and <a href="http://clinicaltrials.bayer.com" target="_blank">clinicaltrials.bayer.com</a> in June 2023 for registered trials, using 'dysmenorrhoea'. We contacted trialists, as they are often a source of unpublished data (<a href="./references#CD002120-bbs2-0061" title="SchrollJB , BeroL , GøtzschePC . Searching for unpublished data for Cochrane Reviews: cross sectional study. BMJ2013;346:f2231. [DOI: 10.1136/bmj.f2231]">Schroll 2013</a>). It is usually recommended that review teams contact regulatory agencies (<a href="./references#CD002120-bbs2-0062" title="SchrollJ , BeroL . Regulatory agencies hold the key to improving Cochrane Reviews of drugs. Cochrane Database of Systematic Reviews2015, Issue 4. [DOI: 10.1002/14651858.ED000098]">Schroll 2015</a>), but since OCPs are not approved for dysmenorrhoea, we chose not to approach regulatory agencies. We also screened the reference lists of relevant studies for any additional trials. </p> </section> </section> <section id="CD002120-sec-0030"> <h3 class="title" id="CD002120-sec-0030">Data collection and analysis</h3> <section id="CD002120-sec-0031"> <h4 class="title">Selection of studies</h4> <p>After two review authors (JBS and IC) independently conducted the initial screen of titles and abstracts retrieved by the search, we retrieved the full texts of all potentially eligible studies. Two review authors (JBS and IC) independently examined these full‐text articles for compliance with the inclusion criteria, and selected eligible studies. We corresponded with study investigators as required, to clarify study eligibility. We resolved disagreements by discussion. If any reports required translation, we described the process used for data collection. We documented the selection process in a PRISMA flow chart (<a href="#CD002120-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD002120-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA flowchart." data-id="CD002120-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flowchart.</p> </div> </div> </div> </section> <section id="CD002120-sec-0032"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (JBS and IC) independently extracted data from eligible studies using a data extraction form designed and pilot‐tested by the review authors. Any disagreements were resolved by discussion, or by a third review author (CF). Data extracted included study characteristics and outcome data (see data extraction table for details in <a href="./appendices#CD002120-sec-0122">Appendix 6</a>). When studies had multiple publications, we used the main trial report as the reference, and derived additional details from secondary papers. We corresponded with study investigators for further data on methods, results, or both, as required. </p> </section> <section id="CD002120-sec-0033"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (JBS and IC) independently assessed the included studies for risk of bias using the Cochrane RoB 1 tool to assess: allocation (random sequence generation and allocation concealment); blinding of participants and personnel; blinding of outcome assessors; incomplete outcome data; selective reporting; and other bias (<a href="./references#CD002120-bbs2-0049" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). We resolved disagreements by discussion, or by a third review author (CF). We described all judgements fully and presented the conclusions in the risk of bias table, which we used to assess the quality of evidence and incorporated it into the interpretation of review findings using sensitivity analyses (see below). For more information on how the different risk of bias domains where interpreted, see <a href="./appendices#CD002120-sec-0123">Appendix 7</a>. </p> <p>We assessed within‐trial selective reporting, such as trials failing to report obvious outcomes, or reporting them in insufficient detail to allow inclusion. We sought published protocols and compared the outcomes between the protocol and the final published study. </p> <p>We included sponsor bias as a domain, because industry sponsored trials more often show beneficial results, which cannot be explained by the usual domains (<a href="./references#CD002120-bbs2-0055" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. Art. No: MR000033. [DOI: 10.1002/14651858.MR000033.pub3]">Lundh 2017</a>). </p> </section> <section id="CD002120-sec-0034"> <h4 class="title">Measures of treatment effect</h4> <p>When extracting data from the trials for the outcome of pain relief, we decided, a priori, to only count substantial changes in pain as pain relief, if the trial reported sufficient data. For example, the number of women who reported their severe pain was now mild or no pain on 4‐point scale would be included as experiencing pain relief, but not women changing from severe to moderate pain. We did not dichotomise outcomes based on continuous outcomes. </p> <p>We chose to use risk ratio (RR), as odds ratio (OR) is difficult to interpret when there are many events. For continuous data (e.g. weight gain), when all studies reported the same outcomes using the same measurement tools, we calculated the mean difference (MDs) between treatment groups. If studies reported similar outcomes using different scales (e.g. change in weight), we calculate the standardised mean difference (SMD). </p> <p>We planned to reverse the direction of effect of individual studies, if required, to ensure consistency across trials. We treated ordinal data (e.g. quality of life scores) as continuous data. We presented 95% confidence intervals (CI) for all outcomes. When data to calculate RRs or MDs were not available, we used the most detailed numerical data available that could facilitate similar analyses of included studies (e.g. test statistics, P values). In each case, we assessed whether the estimates for individual studies calculated in the review were compatible with the estimates reported in the study publications. </p> </section> <section id="CD002120-sec-0035"> <h4 class="title">Unit of analysis issues</h4> <p>The primary analysis was per woman randomised.</p> </section> <section id="CD002120-sec-0036"> <h4 class="title">Dealing with missing data</h4> <p>We analysed the data on an intention‐to‐treat (ITT) basis as far as possible (i.e. including all randomised participants in analysis, in the groups to which they were randomised). We attempted to obtain missing data from the original trialists. We calculated missing standard deviations (SD) using the methods available in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD002120-bbs2-0050" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022</a>). </p> </section> <section id="CD002120-sec-0037"> <h4 class="title">Assessment of heterogeneity</h4> <p>We considered whether the clinical and methodological characteristics of the included studies were sufficiently similar for meta‐analysis to provide a clinically meaningful summary. We assessed statistical heterogeneity by calculating the I² statistic. We considered an I² statistic greater than 50% as substantial heterogeneity (<a href="./references#CD002120-bbs2-0050" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022</a>). </p> <p>A priori, we planned to consider the possible contribution of differences in trial design to any heterogeneity identified in this manner. Where possible, we pooled the outcomes in analyses. </p> </section> <section id="CD002120-sec-0038"> <h4 class="title">Assessment of reporting biases</h4> <p>In view of the difficulty of detecting and correcting for publication bias and other reporting biases, we aimed to minimise their potential impact by ensuring a comprehensive search for eligible studies, and by being alert for duplication of data. If there were 10 or more studies in an analysis, we planned to use a funnel plot to explore the possibility of small‐study effects (a tendency for estimates of the intervention effect to be more beneficial in smaller studies). </p> </section> <section id="CD002120-sec-0039"> <h4 class="title">Data synthesis</h4> <p>We undertook statistical analysis in accordance with the guidelines for statistical analysis developed by Cochrane and published in <i>Cochrane Handbook for Systematic Reviews of Interventions</i>. </p> <p>For dichotomous data (e.g. proportion of women with a specific adverse effect), we expressed the results for each study as an RR with 95% CIs, and combined the data for meta‐analysis using Review Manager 5, using the Mantel‐Haenszel method (<a href="./references#CD002120-bbs2-0060" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>). </p> <p>We showed continuous differences between groups in the meta‐analysis as MDs when studies used the same scales; we used SMDs if studies used difference scales. We used a fixed‐effect model for the primary analysis. </p> <p>If studies used other scales or labels, we collapsed them into dichotomous data, if possible, based on the authors' descriptions of the scale. If outcomes were presented in terms of pain intensity, rather than pain relief, we considered them, and where possible, converted them into dichotomous categories. </p> <p>We planned the following analyses:</p> <p> <ol id="CD002120-list-0009"> <li> <p>OCP versus placebo or no treatment</p> </li> <li> <p>OCP versus another OCP</p> </li> <li> <p>OCP versus NSAIDs</p> </li> </ol> </p> </section> <section id="CD002120-sec-0040"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>The protocol planned no subgroup analyses. OCPs were grouped according to oestrogen dose and progestogen generation. </p> <p>When comparing OCPs to different OCPs, it made biological sense to subgroup the studies into continuous regimen versus standard regimen, low dose versus high dose, and third generation versus fourth generation. We made this decision after the search was completed. </p> </section> <section id="CD002120-sec-0041"> <h4 class="title">Sensitivity analysis</h4> <p>We planned sensitivity analyses for our primary outcomes by removing studies at high or unclear risk of bias for allocation concealment. </p> <p>When we observed statistical heterogeneity, we assessed sensitivity to the choice of model by comparing results with a random‐effects analysis. </p> </section> <section id="CD002120-sec-0042"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We generated summary of findings tables using GRADEpro GDT software (<a href="./references#CD002120-bbs2-0047" title="GRADEpro GDT. Version accessed 2 August 2019. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a>). These tables evaluated the overall quality of the body of evidence for main review outcomes, using GRADE criteria (study limitations (i.e. risk of bias), consistency of effect, imprecision, indirectness, and publication bias). We justified, documented, and incorporated judgements about the quality of the evidence into reporting of results (high, moderate, low, or very low). </p> <p>We included the following outcomes in each summary of findings table: pain score, pain improvement, any adverse events, serious adverse events, irregular bleeding, headaches, nausea, weight gain, requirement for additional medication, and absence from work or school. </p> <p>We produced three summary of findings tables.</p> <p> <ol id="CD002120-list-0010"> <li> <p>Combined OCP versus placebo or no treatment</p> </li> <li> <p>Combined OCP versus another OCP</p> </li> <li> <p>Combined OCP versus NSAIDs</p> </li> </ol> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD002120-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD002120-sec-0043"></div> <section id="CD002120-sec-0044"> <h3 class="title">Description of studies</h3> <section id="CD002120-sec-0045"> <h4 class="title">Results of the search</h4> <p>In this update, our searches found 1128 articles after the removal of duplicates. Twenty‐six reports were potentially eligible, and we retrieved them in full text. Fourteen new trials met our inclusion criteria. We excluded 11 reports and one study is ongoing. This update included 21 studies. One study was not designed in a way that could provide usable data, so we were unable to include the data in the quantitative analysis (<a href="./references#CD002120-bbs2-0002" title="BassolS , AlvaradoA , CelisC , CraviotoMC , PeraltaO , MontanoR , et al. Latin American experience with two low-dose oral contraceptives containing 30µg ethinylestradiol/75µg gestodene and 20µg ethinyl estradiol/150µg desogestrel. Contraception2000;62(3):131-5. ">Bassol 2000</a>). See <a href="./references#CD002120-sec-0135" title="">Characteristics of included studies</a> table, <a href="./references#CD002120-sec-0136" title="">Characteristics of excluded studies</a> table, <a href="./references#CD002120-sec-0137" title="">Characteristics of ongoing studies</a> table, and <a href="#CD002120-fig-0001">Figure 1</a>. </p> </section> <section id="CD002120-sec-0046"> <h4 class="title">Included studies</h4> <section id="CD002120-sec-0047"> <h5 class="title">Study design and setting</h5> <p>We included 21 RCTs in this review update. The included studies were conducted in Japan, the Philippines, Thailand, the UK, Sweden, Croatia, Germany, Italy, Turkey, Argentina, Mexico, Chile, Venezuela, Brazil, the USA, and Canada, from 1966 to 2017. Six were single site studies, two were unclear, and 13 were multicentre studies. One study was a cross‐over design, which randomised women every month to a treatment. The women were followed for three to six months (<a href="./references#CD002120-bbs2-0017" title="NakanoR , TakemuraH . Treatment of function dysmenorrhoea: a double-blind study. Acta Obstetrica et Gynaecologica Japonica1971;18(1):41-4. ">Nakano 1971</a>). Due to a lack of washout between phases, it was only possible to use the initial phase; the study included 18 women. The other studies followed a parallel design. </p> <p>Three studies were only available to us through <a href="https://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a>. One study was completely unpublished (<a href="./references#CD002120-bbs2-0007" title="NCT00196313. A study to evaluate the efficacy of Seasonique for the treatment of cyclic pelvic pain [A multicenter study to compare the efficacy of an extended-cycle oral contraceptive, Seasonique, which utilizes ethinyl estradiol during the usual hormone-free interval to placebo for the treatment of cyclic pelvic pain in adolescents]. clinicaltrials.gov/ct2/show/study/NCT00196313 (first posted 20 September 2005). ">Duramed 2008</a>), and two studies were published only in Japanese journals that are not indexed in PubMed (<a href="./references#CD002120-bbs2-0014" title="MomoedaM , HayakawaM , ShimazakiY , MizunumaH , TaketaniY . Does the presence of coexisting diseases modulate the effectiveness of a low-dose estrogen/progestin, ethinylestradiol/drospirenone combination tablet in dysmenorrhea? Reanalysis of two randomized studies in Japanese women. International Journal of Women's Health2014;6:989-98. MomoedaM , MizunumaH , TaketaniY . Long term efficacy and safety of drospirenone/ethinylestradiol combination (YAZ) tablets for patients with dysmenorrhea: Shinryo to Shinyaku. Medical Consult and New Remedies [Japanese version]2010;47:1003-15. ">Momoeda 2010a</a>; <a href="./references#CD002120-bbs2-0015" title="MomoedaM , HayakawaM , ShimazakiY , MizunumaH , TaketaniY . Does the presence of coexisting diseases modulate the effectiveness of a low-dose estrogen/progestin, ethinylestradiol/drospirenone combination tablet in dysmenorrhea? Reanalysis of two randomized studies in Japanese women. International Journal of Women's Health2014;6:989-98. MomoedaM , MizunumaH , TaketaniY . Treatment of functional and organic dysmenorrhea: efficacy and safety of drospirenone/ethinylestradiol combination tablet: Sanka to Fujinka. Obstetrics and Gynecology [Japanese version]2010;77:977-88. ">Momoeda 2010b</a>). The author sent us Japanese versions of the manuscript that we were able to translate. </p> </section> <section id="CD002120-sec-0048"> <h5 class="title">Participants</h5> <p>The studies included 3723 women with at least moderate‐degree dysmenorrhoea. Some studies also included women with secondary dysmenorrhoea, but we only included data in our meta‐analysis if they were reported separately for women with primary dysmenorrhoea. The mean age ranged from 15 to 33 years across the included studies. </p> </section> <section id="CD002120-sec-0049"> <h5 class="title">Interventions</h5> <p>Eleven studies compared the combined OCP with placebo (<a href="./references#CD002120-bbs2-0003" title="ButtramVC , KaufmanRH . Primary dysmenorrhoea: combination vs sequential therapy. Texas Medicine1969;65(8):52-5. ">Buttram 1969</a>; <a href="./references#CD002120-bbs2-0004" title="CullbergJ . Mood changes and menstrual symptoms with different gestagen/estrogen combinations. Acta Psychiatrica Scandinavia Supplementum1972;236:1-86. ">Cullberg 1972</a>; <a href="./references#CD002120-bbs2-0005" title="DavisAR , OsborneLM , O'ConnellKJ , WesthoffCL . Challenges of conducting a placebo-controlled trial for dysmenorrhea in adolescents. Journal of Adolescent Health2006;39:607-9. [DOI: 10.101.16/j.jadohealth.2006.03.019]DavisAR , WesthoffC , O'ConnellK , CallagherN . Oral contraceptives for dysmenorrhea in adolescent girls: a randomized trial. Obstetrics &amp; Gynecology2005;106(1):97-104. O'ConnellK , DavidAR , KernsJ . Oral contraceptives: side effects and depression in adolescent girls. Contraception2007;75:299-304. [DOI: 10.1016/j.contraception.2006.09.008]">Davis 2005</a>; <a href="./references#CD002120-bbs2-0007" title="NCT00196313. A study to evaluate the efficacy of Seasonique for the treatment of cyclic pelvic pain [A multicenter study to compare the efficacy of an extended-cycle oral contraceptive, Seasonique, which utilizes ethinyl estradiol during the usual hormone-free interval to placebo for the treatment of cyclic pelvic pain in adolescents]. clinicaltrials.gov/ct2/show/study/NCT00196313 (first posted 20 September 2005). ">Duramed 2008</a>; <a href="./references#CD002120-bbs2-0008" title="General Practitioner Research Group. Dysmenorrhoea unrelieved by an oral contraceptive. Practitioner1968;200:856-9. ">GPRG 1968</a>; <a href="./references#CD002120-bbs2-0009" title="HaradaT , MomoedaM , TerakawaN , TaketaniY , HoshiaiH . Evaluation of a low-dose oral contraceptive pill for primary dysmenorrhea: a placebo-controlled, double-blind, randomized trial. Fertility and Sterility2011;95(6):1928-31. ">Harada 2011</a>; <a href="./references#CD002120-bbs2-0010" title="HaradaT , MomoedaM . Evaluation of an ultra-low-dose oral contraceptive for dysmenorrhea: a placebo-controlled, double-blind, randomized trial. Fertility and Sterility2016;106(7):1807-14. [DOI: doi: 10.1016/j.fertnstert.2016.08.051.]">Harada 2016</a>; <a href="./references#CD002120-bbs2-0012" title="HendrixSL , AlexanderNJ . Primary dysmenorrhea treatment with a desogestrel-containing low-dose oral contraceptive. Contraception2002;66(6):393-9. ">Hendrix 2002</a>; <a href="./references#CD002120-bbs2-0015" title="MomoedaM , HayakawaM , ShimazakiY , MizunumaH , TaketaniY . Does the presence of coexisting diseases modulate the effectiveness of a low-dose estrogen/progestin, ethinylestradiol/drospirenone combination tablet in dysmenorrhea? Reanalysis of two randomized studies in Japanese women. International Journal of Women's Health2014;6:989-98. MomoedaM , MizunumaH , TaketaniY . Treatment of functional and organic dysmenorrhea: efficacy and safety of drospirenone/ethinylestradiol combination tablet: Sanka to Fujinka. Obstetrics and Gynecology [Japanese version]2010;77:977-88. ">Momoeda 2010b</a>; <a href="./references#CD002120-bbs2-0017" title="NakanoR , TakemuraH . Treatment of function dysmenorrhoea: a double-blind study. Acta Obstetrica et Gynaecologica Japonica1971;18(1):41-4. ">Nakano 1971</a>; <a href="./references#CD002120-bbs2-0018" title="OsugaY , HayashiK , KandaS . Evaluation of the efficacy, safety, and clinically recommended dose of dienogest in the treatment of primary dysmenorrhea: a randomized, double-blind, multicenter, placebo-controlled study. Fertility and Sterility2020;113(1):167-75. [DOI: 10.1016/j.fertnstert.2019.09.014]">Osuga 2020</a>); one compared two OCP regimens with placebo (<a href="./references#CD002120-bbs2-0011" title="HaradaT , MomoedaM . Efficacy of cyclic and extended regimens of ethinylestradiol 0.02 mg-levonorgestrel 0.09 mg for dysmenorrhea: a placebo-controlled, double-blind, randomized trial. Reproductive Medicine and Biology2021;20(2):215-23. [DOI: 10.1002/rmb2.12373]">Harada 2021</a>); eight compared different dosages of combined OCP (<a href="./references#CD002120-bbs2-0002" title="BassolS , AlvaradoA , CelisC , CraviotoMC , PeraltaO , MontanoR , et al. Latin American experience with two low-dose oral contraceptives containing 30µg ethinylestradiol/75µg gestodene and 20µg ethinyl estradiol/150µg desogestrel. Contraception2000;62(3):131-5. ">Bassol 2000</a>; <a href="./references#CD002120-bbs2-0006" title="DmitrovicR , KunselmanAR , LegroRS . Continuous compared with cyclic oral contraceptives for the treatment of primary dysmenorrhea: a randomized controlled trial. Obstetrics &amp; Gynecology2012;119(6):1143-50. ">Dmitrovic 2012</a>; <a href="./references#CD002120-bbs2-0013" title="JaisamrarnU , SantibenchakulS . A comparison of combined oral contraceptives containing chlormadinone acetate versus drospirenone for the treatment of acne and dysmenorrhea: a randomized trial. Contraception and Reproductive Medicine2018;10(3):5. [DOI: 10.1186/s40834-018-0058-9]">Jaisamrarn 2018</a>; <a href="./references#CD002120-bbs2-0014" title="MomoedaM , HayakawaM , ShimazakiY , MizunumaH , TaketaniY . Does the presence of coexisting diseases modulate the effectiveness of a low-dose estrogen/progestin, ethinylestradiol/drospirenone combination tablet in dysmenorrhea? Reanalysis of two randomized studies in Japanese women. International Journal of Women's Health2014;6:989-98. MomoedaM , MizunumaH , TaketaniY . Long term efficacy and safety of drospirenone/ethinylestradiol combination (YAZ) tablets for patients with dysmenorrhea: Shinryo to Shinyaku. Medical Consult and New Remedies [Japanese version]2010;47:1003-15. ">Momoeda 2010a</a>; <a href="./references#CD002120-bbs2-0016" title="MomoedaM , KondoM , ElliesenJ , YasudaM , YamamotoS , HaradaT . Efficacy and safety of a flexible extended regimen of ethinylestradiol/drospirenone for the treatment of dysmenorrhea: a multicenter, randomized, open-label, active-controlled study. International Journal of Women's Health2017;2;9:295-305. [DOI: 10.2147/IJWH.S134576]">Momoeda 2017</a>; <a href="./references#CD002120-bbs2-0019" title="PetragliaF , ParkeS , SerraniM , MellingerU , RömerT . Estradiol valerate plus dienogest versus ethinylestradiol plus levonorgestrel for the treatment of primary dysmenorrhea. International Journal of Gynecology &amp; Obstetrics2014;125(3):270-4. [DOI: 10.1016/j.ijgo.2013.11.017]">Petraglia 2014</a>; <a href="./references#CD002120-bbs2-0020" title="StrowitzkiT , KirschB , ElliesenJ . Efficacy of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen in women with moderate-to-severe primary dysmenorrhoea: an open-label, multicentre, randomised, controlled study. Journal of Family Planning and Reproductive Health Care2012;38(2):94-101. [DOI: 10.1136/jfprhc-2011-100225.]">Strowitzki 2012</a>; <a href="./references#CD002120-bbs2-0021" title="UysalG , AkkayaH , CagliF , TutusS , TayyarAT . A comparison of two different oral contraceptives in patients with severe primary dysmenorrhoea. Journal of Obstetrics and Gynaecology2018;38(6):828-32. [DOI: 10.1080/01443615.2017.1410533]">Uysal 2018</a>); and one compared OCP to NSAIDs (<a href="./references#CD002120-bbs2-0001" title="AydoğmusS , KeskinHL , AydoğmusH , CelenE , AckayGY , SivaslioğluAA , et al. Can extracorporeal magnetic innervation be a treatment modality for primary dysmenorrhea?Gynecologic and Obstetric Investigation2014;77(4):250-4. [DOI: 10.1159/000360906]">Aydogmus 2014</a>). </p> <p>Four studies used older OCPs, which contained more than 30 μg of oestrogen (medium dose). They were considerably older than the other studies (<a href="./references#CD002120-bbs2-0003" title="ButtramVC , KaufmanRH . Primary dysmenorrhoea: combination vs sequential therapy. Texas Medicine1969;65(8):52-5. ">Buttram 1969</a>; <a href="./references#CD002120-bbs2-0004" title="CullbergJ . Mood changes and menstrual symptoms with different gestagen/estrogen combinations. Acta Psychiatrica Scandinavia Supplementum1972;236:1-86. ">Cullberg 1972</a>; <a href="./references#CD002120-bbs2-0008" title="General Practitioner Research Group. Dysmenorrhoea unrelieved by an oral contraceptive. Practitioner1968;200:856-9. ">GPRG 1968</a>; <a href="./references#CD002120-bbs2-0017" title="NakanoR , TakemuraH . Treatment of function dysmenorrhoea: a double-blind study. Acta Obstetrica et Gynaecologica Japonica1971;18(1):41-4. ">Nakano 1971</a>). </p> <p>Among the studies comparing different OCPs, five compared a continuous regimen of OCPs (without a pause after 21 days of hormone treatment) with a standard regimen (<a href="./references#CD002120-bbs2-0006" title="DmitrovicR , KunselmanAR , LegroRS . Continuous compared with cyclic oral contraceptives for the treatment of primary dysmenorrhea: a randomized controlled trial. Obstetrics &amp; Gynecology2012;119(6):1143-50. ">Dmitrovic 2012</a>; <a href="./references#CD002120-bbs2-0011" title="HaradaT , MomoedaM . Efficacy of cyclic and extended regimens of ethinylestradiol 0.02 mg-levonorgestrel 0.09 mg for dysmenorrhea: a placebo-controlled, double-blind, randomized trial. Reproductive Medicine and Biology2021;20(2):215-23. [DOI: 10.1002/rmb2.12373]">Harada 2021</a>; <a href="./references#CD002120-bbs2-0011" title="HaradaT , MomoedaM . Efficacy of cyclic and extended regimens of ethinylestradiol 0.02 mg-levonorgestrel 0.09 mg for dysmenorrhea: a placebo-controlled, double-blind, randomized trial. Reproductive Medicine and Biology2021;20(2):215-23. [DOI: 10.1002/rmb2.12373]">Harada 2021</a>; <a href="./references#CD002120-bbs2-0016" title="MomoedaM , KondoM , ElliesenJ , YasudaM , YamamotoS , HaradaT . Efficacy and safety of a flexible extended regimen of ethinylestradiol/drospirenone for the treatment of dysmenorrhea: a multicenter, randomized, open-label, active-controlled study. International Journal of Women's Health2017;2;9:295-305. [DOI: 10.2147/IJWH.S134576]">Momoeda 2017</a>; <a href="./references#CD002120-bbs2-0020" title="StrowitzkiT , KirschB , ElliesenJ . Efficacy of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen in women with moderate-to-severe primary dysmenorrhoea: an open-label, multicentre, randomised, controlled study. Journal of Family Planning and Reproductive Health Care2012;38(2):94-101. [DOI: 10.1136/jfprhc-2011-100225.]">Strowitzki 2012</a>). </p> <p>The included studies assessed the following progestins: norethisterone, norethindrone, chlormadinone, norgestrel, levonorgestrel, desogestrel, gestodene, drospirenone, and dienogest. </p> <p>Treatment duration of studies with usable data ranged from one to six months.</p> </section> <section id="CD002120-sec-0050"> <h5 class="title">Outcomes</h5> <p>For our first comparison, OCP versus placebo, 6/12 studies reported post‐treatment values of pain as a continuous outcome. Five of the six studies were conducted in Japan, and used the Total Dysmenorrhoea Scale (7‐point scale; range 0 to 6). Six studies reported pain improvement as a dichotomous outcome. This could have been an improvement in lower abdominal pain, and sometimes it was unclearly defined. All eight of the newer studies (published after 2000) reported usable data on adverse events. </p> <p>For our second comparison, OCP versus OCP, three of eight studies reported pain post‐treatment as a continuous outcome, and two of eight studies reported improvement as a dichotomous outcome. </p> <p>For the third comparison, OCP versus NSAIDs, one study reported improvement as a continuous outcome only. </p> </section> </section> <section id="CD002120-sec-0051"> <h4 class="title">Excluded studies</h4> <p>Overall we excluded 19 studies from this review. We excluded three studies from the 2009 version of this Cochrane Review because they included healthy women (<a href="./references#CD002120-bbs2-0024" title="EndrikatJ , DusterbergB , RuebigA , GerlingerC , StrowitzkiT . Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study. Contraception1999;60(5):269-74. ">Endrikat 1999</a>; <a href="./references#CD002120-bbs2-0037" title="SerfatyD , VreeML . A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 20 μg ethinylestradiol and either 150 μg desogestrel or 75 μg gestodene. European Journal of Contraception and Reproductive Health Care1998;3(4):179-89. ">Serfaty 1998</a>; <a href="./references#CD002120-bbs2-0039" title="WinklerUH , FergusonH , MuldersJA . Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 µg ethinylestradiol. Contraception2004;69(6):469-76. ">Winkler 2004</a>). Information about pain during menstruation was recorded, but since these women had not contacted a health professional, we did not consider these studies to be eligible for this review. </p> <p>We excluded three further studies at this update: one was a conference abstract with no data, and we had no response when contact was attempted (<a href="./references#CD002120-bbs2-0022" title="BrownR , ReapeK , ShuH . Effectiveness of an extended-regimen oral contraceptive for the treatment of moderate to severe pelvic pain in adolescents. Contraception2009;80:215. ">Brown 2009</a>); one included women with secondary dysmenorrhoea, so did not meet our inclusion criteria (<a href="./references#CD002120-bbs2-0034" title="MomoedaM , HayakawaM , ShimazakiY , MizunumaH , TaketaniY . Does the presence of coexisting diseases modulate the effectiveness of a low-dose estrogen/progestin, ethinylestradiol/drospirenone combination tablet in dysmenorrhea? Reanalysis of two randomized studies in Japanese women. International Journal of Womens Health2014;6:989-98. [DOI: 10.2147/IJWH.S70935]">Momoeda 2014</a>); and one primarily included healthy women, not women with dysmenorrhoea (<a href="./references#CD002120-bbs2-0040" title="WitjesH , CreininMD , Sundström-PoromaaI , Martin NguyenA , KorverT . Comparative analysis of the effects of nomegestrol acetate/17 β-estradiol and drospirenone/ethinylestradiol on premenstrual and menstrual symptoms and dysmenorrhea. European Journal of Contraception &amp; Reproductive Health Care2015;20(4):296-307. [DOI: 10.3109/13625187.2015.1016154]">Witjes 2015</a>). We excluded studies investigating intrauterine devices, vaginal rings, or progestin‐only tablets. </p> </section> <section id="CD002120-sec-0052"> <h4 class="title">Ongoing studies</h4> <p>We found one ongoing study (<a href="./references#CD002120-bbs2-0041" title="NCT00196365. A study to evaluate the efficacy of Seasonique for the treatment of cyclic pelvic pain [A study to compare the efficacy of an extended-cycle oral contraceptive, Seasonique, which utilizes ethinyl estradiol during the usual hormone-free interval compared to conventional oral contraceptive therapy for cyclic pelvic pain]. clinicaltrials.gov/ct2/show/NCT00196365 (first received 20 September 2005). ">NCT00196365</a>). </p> </section> </section> <section id="CD002120-sec-0053"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD002120-fig-0002">Figure 2</a> and <a href="#CD002120-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD002120-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Review authors' judgements about each risk of bias, presented as percentages across all included studies." data-id="CD002120-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Review authors' judgements about each risk of bias, presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD002120-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Review authors' judgements about each risk of bias for each included study." data-id="CD002120-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Review authors' judgements about each risk of bias for each included study.</p> </div> </div> </div> <section id="CD002120-sec-0054"> <h4 class="title">Allocation</h4> <section id="CD002120-sec-0055"> <h5 class="title">Sequence generation</h5> <p>Nine studies had unclear risk of bias for sequence generation. One study was at high risk, as generation was "according to the order the doctor took out bottles from the containers" (<a href="./references#CD002120-bbs2-0008" title="General Practitioner Research Group. Dysmenorrhoea unrelieved by an oral contraceptive. Practitioner1968;200:856-9. ">GPRG 1968</a>). All the older studies (published before 2000), and the unpublished studies were at unclear or high risk. The remaining studies stated that they used randomisation. </p> </section> <section id="CD002120-sec-0056"> <h5 class="title">Allocation concealment</h5> <p>Thirteen studies had unclear risk of bias for allocation concealment. The remaining studies used some type of computer allocation (sometimes centrally), in which case, we assessed allocation concealment at low risk of bias. </p> </section> </section> <section id="CD002120-sec-0057"> <h4 class="title">Blinding</h4> <section id="CD002120-sec-0058"> <h5 class="title">Performance bias</h5> <p>Ten studies performed blinding of investigators and participants and an additional two studies were blinded for investigators only. These 12 studies were at low risk of performance bias. However, in one of these studies, participants were fairly easily able to guess their allocation, as one group would be expected to get withdrawal bleeding, while the other would not (<a href="./references#CD002120-bbs2-0006" title="DmitrovicR , KunselmanAR , LegroRS . Continuous compared with cyclic oral contraceptives for the treatment of primary dysmenorrhea: a randomized controlled trial. Obstetrics &amp; Gynecology2012;119(6):1143-50. ">Dmitrovic 2012</a>). In four studies, risk of bias was unclear, and five studies were open‐label and were at high risk of bias. </p> </section> <section id="CD002120-sec-0059"> <h5 class="title">Detection bias</h5> <p>Our primary outcome was participant‐reported and we assessed the risk of detection bias as high in seven studies where participants were not blinded. In four studies, risk of bias was unclear and in the remaining 10 studies risk of bias was low. </p> </section> </section> <section id="CD002120-sec-0060"> <h4 class="title">Incomplete outcome data</h4> <p>In three studies, we assessed the risk of attrition bias as unclear, which represented cases in which we did not find major unbalanced dropouts, but ITT analyses were not conducted. We assessed one study at high risk of attrition bias, as there were seven dropouts in the first group, compared to 23 in the second (<a href="./references#CD002120-bbs2-0016" title="MomoedaM , KondoM , ElliesenJ , YasudaM , YamamotoS , HaradaT . Efficacy and safety of a flexible extended regimen of ethinylestradiol/drospirenone for the treatment of dysmenorrhea: a multicenter, randomized, open-label, active-controlled study. International Journal of Women's Health2017;2;9:295-305. [DOI: 10.2147/IJWH.S134576]">Momoeda 2017</a>). We assessed the remaining studies at low risk. </p> </section> <section id="CD002120-sec-0061"> <h4 class="title">Selective reporting</h4> <p>We assessed three studies at high risk of reporting bias. In <a href="./references#CD002120-bbs2-0013" title="JaisamrarnU , SantibenchakulS . A comparison of combined oral contraceptives containing chlormadinone acetate versus drospirenone for the treatment of acne and dysmenorrhea: a randomized trial. Contraception and Reproductive Medicine2018;10(3):5. [DOI: 10.1186/s40834-018-0058-9]">Jaisamrarn 2018</a>, the primary outcomes were not specified and there was no protocol registered in clinical trials registry databases. According to the record in ClinicalTrials.gov, <a href="./references#CD002120-bbs2-0010" title="HaradaT , MomoedaM . Evaluation of an ultra-low-dose oral contraceptive for dysmenorrhea: a placebo-controlled, double-blind, randomized trial. Fertility and Sterility2016;106(7):1807-14. [DOI: doi: 10.1016/j.fertnstert.2016.08.051.]">Harada 2016</a> changed the measurement of the primary outcome from "VRS" (as reported on ClinicalTrials.gov) to a Total Dysmenorrhoea Score. <a href="./references#CD002120-bbs2-0004" title="CullbergJ . Mood changes and menstrual symptoms with different gestagen/estrogen combinations. Acta Psychiatrica Scandinavia Supplementum1972;236:1-86. ">Cullberg 1972</a> did not report the primary outcome because of a post hoc analysis. For the remaining studies, we assessed the risk of selective reporting bias as unclear or low. </p> </section> <section id="CD002120-sec-0062"> <h4 class="title">Other potential sources of bias</h4> <section id="CD002120-sec-0063"> <h5 class="title">Sponsor bias</h5> <p>Eleven studies were sponsored by the manufacturer of the drug, and therefore, we considered them at high risk of bias. We were unsure of the risk of bias in seven studies, and since three studies were funded by other sources, we assessed them at low risk of bias. </p> </section> <section id="CD002120-sec-0064"> <h5 class="title">Other bias</h5> <p>One study was a cross‐over design, but due to lack of a washout period, we only used the initial allocation. It only included 18 women, so its impact on our results was minimal. </p> </section> </section> </section> <section id="CD002120-sec-0065"> <h3 class="title" id="CD002120-sec-0065">Effects of interventions</h3> <p>See: <a href="./full#CD002120-tbl-0001"><b>Summary of findings 1</b> Combined OCP compared to placebo or no treatment for primary dysmenorrhoea</a>; <a href="./full#CD002120-tbl-0002"><b>Summary of findings 2</b> Combined low‐dose OCP compared to another combined low‐dose OCP for primary dysmenorrhoea</a>; <a href="./full#CD002120-tbl-0003"><b>Summary of findings 3</b> NSAID compared to combined OCP for primary dysmenorrhoea</a> </p> <section id="CD002120-sec-0066"> <h4 class="title">1. Combined oral contraceptive pill versus placebo or no treatment</h4> <section id="CD002120-sec-0067"> <h5 class="title">Primary outcomes</h5> <section id="CD002120-sec-0068"> <h6 class="title">1.1 Pain scores</h6> <p>OCPs reduced pain in women with dysmenorrhoea more effectively compared to placebo (SMD −0.58, 95% CI −0.74 to −0.41; I² = 28%; 6 RCTs, 588 women; high‐quality evidence; <a href="./references#CD002120-fig-0008" title="">Analysis 1.1</a>). This was considered a moderate reduction. </p> <p>The results were similar with a random‐effects model (SMD −0.57, 95% CI −0.77 to −0.37; I² = 28%; 6 RCTs, 588 women; <a href="./references#CD002120-fig-0008" title="">Analysis 1.1</a>; <a href="#CD002120-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD002120-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Combined OCP versus placebo or no treatment, outcome: 1.1 Pain score (continuous data)." data-id="CD002120-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Combined OCP versus placebo or no treatment, outcome: 1.1 Pain score (continuous data). </p> </div> </div> </div> <p>Five of the six studies used the Total Dysmenorrhoea Score (range 0 to 6). Using an average SD of 1.68, this equals a reduction of 0.7 to 1.3 on the Total Dysmenorrhoea Score. </p> <p>One trial had severe baseline differences, and we were unable to include the data in our meta‐analysis, as it only reported mean change (<a href="./references#CD002120-bbs2-0012" title="HendrixSL , AlexanderNJ . Primary dysmenorrhea treatment with a desogestrel-containing low-dose oral contraceptive. Contraception2002;66(6):393-9. ">Hendrix 2002</a>). It included 59 women, and found that OCPs led to a reduction in mean change of 13.7 on the Moos Menstrual Distress Questionnaire (MMDQ), compared to a reduction of 6.2 for placebo. The trial reported no evidence of a difference on the MMDQ (P = 0.095). </p> <p>One unpublished study only reported mean change, but used a different scale to that used by <a href="./references#CD002120-bbs2-0012" title="HendrixSL , AlexanderNJ . Primary dysmenorrhea treatment with a desogestrel-containing low-dose oral contraceptive. Contraception2002;66(6):393-9. ">Hendrix 2002</a>. <a href="./references#CD002120-bbs2-0007" title="NCT00196313. A study to evaluate the efficacy of Seasonique for the treatment of cyclic pelvic pain [A multicenter study to compare the efficacy of an extended-cycle oral contraceptive, Seasonique, which utilizes ethinyl estradiol during the usual hormone-free interval to placebo for the treatment of cyclic pelvic pain in adolescents]. clinicaltrials.gov/ct2/show/study/NCT00196313 (first posted 20 September 2005). ">Duramed 2008</a> randomised 95 women to receive either levonorgestrel/ethinylestradiol (EE) or a placebo. They found a larger reduction in pain in the levonorgestrel/EE group (mean change −0.45 (SD 0.06)) compared to the placebo group (mean change −0.19 (SD 058.06)), but performed no statistical testing and for technical reasons the study could not be included in the meta‐analysis. </p> </section> <section id="CD002120-sec-0069"> <h6 class="title">1.2 Pain improvement</h6> <p>When considering pain improvement as a binary outcome, OCPs may reduce pain (RR 1.65, 95% CI 1.29 to 2.10; I² = 69%; 6 RCTs, 717 women; low‐quality evidence; <a href="./references#CD002120-fig-0009" title="">Analysis 1.2</a>; <a href="#CD002120-fig-0005">Figure 5</a>). This corresponds to an absolute risk in the placebo group of 28%, compared to a risk in the treatment group of 47% (37% to 60%). </p> <div class="figure" id="CD002120-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Combined OCP versus placebo or no treatment, outcome: 1.2 Pain improvement." data-id="CD002120-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Combined OCP versus placebo or no treatment, outcome: 1.2 Pain improvement. </p> </div> </div> </div> <p>A random‐effects model gave a similar result with wider CIs due to the substantial amount of heterogeneity (RR 1.56, 95% CI 0.94 to 2.59; I² = 69%; 6 RCTs, 717 women). One study was at high risk of bias for both allocation concealment and blinding (<a href="./references#CD002120-bbs2-0008" title="General Practitioner Research Group. Dysmenorrhoea unrelieved by an oral contraceptive. Practitioner1968;200:856-9. ">GPRG 1968</a>). When we excluded this study, the I² statistic dropped to 58%, and the effect increased slightly (RR 1.93, 95% CI 1.19 to 3.13; 5 RCTs, 628 women). There remained substantial heterogeneity, and it could be argued that a meta‐analysis was not advisable. However, the result was consistent with the first outcome (pain scores) using continuous data. Four of the six trials were published in the 1970s, and used OCPs that are no longer available and had higher doses of oestrogen (EE 35 μg to 70 μg). </p> <p>Two other studies measured pain improvement.</p> <p> <ol id="CD002120-list-0011"> <li> <p><a href="./references#CD002120-bbs2-0005" title="DavisAR , OsborneLM , O'ConnellKJ , WesthoffCL . Challenges of conducting a placebo-controlled trial for dysmenorrhea in adolescents. Journal of Adolescent Health2006;39:607-9. [DOI: 10.101.16/j.jadohealth.2006.03.019]DavisAR , WesthoffC , O'ConnellK , CallagherN . Oral contraceptives for dysmenorrhea in adolescent girls: a randomized trial. Obstetrics &amp; Gynecology2005;106(1):97-104. O'ConnellK , DavidAR , KernsJ . Oral contraceptives: side effects and depression in adolescent girls. Contraception2007;75:299-304. [DOI: 10.1016/j.contraception.2006.09.008]">Davis 2005</a> compared a second‐generation progestin with placebo. The study was government‐funded and found an RR of 1.29 for pain improvement compared to placebo (95% CI 0.98 to 1.70; calculated by review authors). </p> </li> <li> <p><a href="./references#CD002120-bbs2-0015" title="MomoedaM , HayakawaM , ShimazakiY , MizunumaH , TaketaniY . Does the presence of coexisting diseases modulate the effectiveness of a low-dose estrogen/progestin, ethinylestradiol/drospirenone combination tablet in dysmenorrhea? Reanalysis of two randomized studies in Japanese women. International Journal of Women's Health2014;6:989-98. MomoedaM , MizunumaH , TaketaniY . Treatment of functional and organic dysmenorrhea: efficacy and safety of drospirenone/ethinylestradiol combination tablet: Sanka to Fujinka. Obstetrics and Gynecology [Japanese version]2010;77:977-88. ">Momoeda 2010b</a> compared a fourth‐generation progestin with placebo. The drug manufacturer funded the study and found an improvement in pain with treatment compared to placebo (RR 4.56, 95% CI 1.47 to 14.12). </p> </li> </ol> </p> </section> <section id="CD002120-sec-0070"> <h6 class="title">1.3 Adverse events</h6> <p>OCPs probably increase the risk of any adverse events compared to placebo or no treatment (RR 1.31, 95% CI 1.20 to 1.43; I² = 79%; 7 RCTs, 1025 women; moderate‐quality evidence; <a href="./references#CD002120-fig-0010" title="">Analysis 1.3</a>). This corresponds to an absolute risk in the placebo group of 59% compared to a risk in the treatment group of 77% (from 71% to 86%). A random‐effects model did not change the result (RR 1.34, 95% CI 1.11 to 1.61; I² = 79%; 7 RCTs, 1025 women). </p> <p>Due to few events, we are uncertain if OCPs lead to serious adverse events (RR 1.77, 95% CI 0.49 to 6.43; I² = 22%; 3 RCTs, 512 women; low‐quality evidence; <a href="./references#CD002120-fig-0010" title="">Analysis 1.3</a>; <a href="#CD002120-fig-0006">Figure 6</a>; note: 4 studies reported serious adverse events but 1 study recorded 0 events in both groups. Thus, the RR and CIs were calculated from 3 studies rather than 4). </p> <div class="figure" id="CD002120-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Combined OCP versus placebo or no treatment, outcome: 1.3 Adverse events." data-id="CD002120-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Combined OCP versus placebo or no treatment, outcome: 1.3 Adverse events. </p> </div> </div> </div> <p>Women who received OCPs had an increased risk of irregular bleeding compared to women who received placebo (RR 2.63, 95% CI 2.11 to 3.28; I² = 29%; 7 RCTs, 1025 women; high‐quality evidence; <a href="./references#CD002120-fig-0010" title="">Analysis 1.3</a>). This corresponds to an absolute risk in the placebo group of 18% compared to a risk in the treatment group of 48% (from 39% to 60%). The random‐effects model found similar results (RR 2.58, 95% CI 1.96 to 3.40; I² = 29%; 7 RCTs, 1025 women). Not all studies described irregular bleeding well. <a href="./references#CD002120-bbs2-0015" title="MomoedaM , HayakawaM , ShimazakiY , MizunumaH , TaketaniY . Does the presence of coexisting diseases modulate the effectiveness of a low-dose estrogen/progestin, ethinylestradiol/drospirenone combination tablet in dysmenorrhea? Reanalysis of two randomized studies in Japanese women. International Journal of Women's Health2014;6:989-98. MomoedaM , MizunumaH , TaketaniY . Treatment of functional and organic dysmenorrhea: efficacy and safety of drospirenone/ethinylestradiol combination tablet: Sanka to Fujinka. Obstetrics and Gynecology [Japanese version]2010;77:977-88. ">Momoeda 2010b</a> reported almost twice as many days with spotting within 90 days in the active group, and almost twice as many women experienced intracyclic bleeding based on participants' diaries. Women in the active arm were more likely to have 'non‐heavy' bleeding. <a href="./references#CD002120-bbs2-0018" title="OsugaY , HayashiK , KandaS . Evaluation of the efficacy, safety, and clinically recommended dose of dienogest in the treatment of primary dysmenorrhea: a randomized, double-blind, multicenter, placebo-controlled study. Fertility and Sterility2020;113(1):167-75. [DOI: 10.1016/j.fertnstert.2019.09.014]">Osuga 2020</a> found that days with bleeding diminished over time. </p> <p>OCPs probably increase the risk of headaches (RR 1.51, 95% CI 1.11 to 2.04; I² = 44%; 5 RCTs, 656 women; moderate‐quality evidence; <a href="./references#CD002120-fig-0010" title="">Analysis 1.3</a>). This corresponds to an absolute risk in the placebo group of 17% compared to a risk in the treatment group of 26% (from 19% to 35%). The random‐effects model found a larger risk (RR 1.65, 95% CI 0.99 to 2.74; I² = 44%; 5 RCTs, 656 women). <a href="./references#CD002120-bbs2-0010" title="HaradaT , MomoedaM . Evaluation of an ultra-low-dose oral contraceptive for dysmenorrhea: a placebo-controlled, double-blind, randomized trial. Fertility and Sterility2016;106(7):1807-14. [DOI: doi: 10.1016/j.fertnstert.2016.08.051.]">Harada 2016</a> reported a significantly increased risk of headaches on ClinicalTrials.gov, but reported no difference between groups in the published report; there was no discussion about the discrepancy. No studies reported more women with headache in the placebo group. </p> <p>Women treated with OCPs probably have an increased risk of nausea (RR 1.64, 95% CI 1.17 to 2.30; I² = 39%; 8 RCTs, 948 women; moderate‐quality evidence; <a href="./references#CD002120-fig-0010" title="">Analysis 1.3</a>). This corresponds to an absolute risk in the placebo group of 10% compared to a risk in the treatment group of 16% (11% to 22%). The random‐effects model found a larger risk, but shifted the CIs (RR 1.70, 95% CI 0.98 to 2.94; I² = 39%; 8 RCTs, 948 women). <a href="./references#CD002120-bbs2-0009" title="HaradaT , MomoedaM , TerakawaN , TaketaniY , HoshiaiH . Evaluation of a low-dose oral contraceptive pill for primary dysmenorrhea: a placebo-controlled, double-blind, randomized trial. Fertility and Sterility2011;95(6):1928-31. ">Harada 2011</a> reported an increased risk and that reduced over time. </p> <p>We are uncertain if OCPs lead to weight gain (RR 1.83, 95% CI 0.75 to 4.45; 1 RCT, 76 women; low‐quality evidence; <a href="./references#CD002120-fig-0010" title="">Analysis 1.3</a>). </p> </section> </section> <section id="CD002120-sec-0071"> <h5 class="title">Secondary outcomes</h5> <section id="CD002120-sec-0072"> <h6 class="title">1.4 Requirement for additional medication</h6> <p>Two studies reported on additional analgesia usage as a dichotomous outcome. There was a 41% relative reduction for women in the treatment group (RR 0.63, 95% CI 0.40 to 0.98; I² = 0%; 2 RCTs, 163 women; <a href="./references#CD002120-fig-0011" title="">Analysis 1.4</a>). </p> <p>One study reported days of additional analgesia use, and the results were uncertain (MD −1.11 days, 95% CI −3.09 to 0.87; 1 RCT, 76 women; <a href="./references#CD002120-fig-0012" title="">Analysis 1.5</a>). </p> </section> <section id="CD002120-sec-0073"> <h6 class="title">1.5 Absence from work or school</h6> <p>Two studies reported on absence from school as a dichotomous outcome. OCPs may slightly reduce absence from work (RR 0.63, 95% CI 0.41 to 0.97; I² = 0%; 2 RCTs, 148 women; low‐quality evidence; <a href="./references#CD002120-fig-0013" title="">Analysis 1.6</a>). However, 95% of the weight of the meta‐analysis came from one trial published in 1968, which used hormone preparations that are not available today (<a href="./references#CD002120-bbs2-0008" title="General Practitioner Research Group. Dysmenorrhoea unrelieved by an oral contraceptive. Practitioner1968;200:856-9. ">GPRG 1968</a>). It is doubtful that conclusions from this study are valid today. </p> <p>One more‐recent study reported on days missed from school/work over 13 weeks, and found a reduction of almost two days amongst the women using OCP (MD −1.92 days, 95% CI −3.14 to −0.70; 1 RCT, 76 women; <a href="./references#CD002120-fig-0014" title="">Analysis 1.7</a>; <a href="./references#CD002120-bbs2-0007" title="NCT00196313. A study to evaluate the efficacy of Seasonique for the treatment of cyclic pelvic pain [A multicenter study to compare the efficacy of an extended-cycle oral contraceptive, Seasonique, which utilizes ethinyl estradiol during the usual hormone-free interval to placebo for the treatment of cyclic pelvic pain in adolescents]. clinicaltrials.gov/ct2/show/study/NCT00196313 (first posted 20 September 2005). ">Duramed 2008</a>). </p> </section> <section id="CD002120-sec-0074"> <h6 class="title">1.6 Withdrawals from treatment</h6> <p>There were no more withdrawals from treatment in the active group compared to placebo (RR 0.92, 95% CI 0.71 to 1.20; I<sup>2</sup> = 33%; 8 RCTs, 931 women; moderate‐quality evidence). </p> </section> <section id="CD002120-sec-0075"> <h6 class="title">1.7 Withdrawal due to adverse events</h6> <p>There was insufficient evidence to determine if there were more withdrawals due to adverse events (RR 1.30, 95% CI 0.64 to 2.62; I<sup>2</sup> = 0%; 7 RCTs, 928 women; low‐quality evidence). </p> </section> </section> <section id="CD002120-sec-0076"> <h5 class="title">Sensitivity analyses</h5> <p>We conducted a series of sensitivity analyses for our primary outcomes by removing studies at high or unclear risk of bias for allocation concealment. </p> <p>For pain reduction, we found similar results to our main analysis (SMD −0.45, 95% CI −0.70 to −0.20; I² = 13%, 3 RCTs, 303 women; <a href="./references#CD002120-fig-0008" title="">Analysis 1.1</a>). Our main analyses seemed unaffected by this risk of bias domain. </p> <p>For pain improvement, we found slightly higher estimates than the main analysis (RR 2.26, 95% CI 1.40 to 3.65; I² = 0%; 1 RCT, 291 women; <a href="./references#CD002120-fig-0009" title="">Analysis 1.2</a>). </p> <p>For any adverse events, we found similar results to our main analysis (RR 1.47, 95% CI 1.29 to 1.67; I² = 85%; 3 RCTs, 518 women; <a href="./references#CD002120-fig-0010" title="">Analysis 1.3</a>). </p> <p>For serious adverse events, there were with very broad CIs (RR 0.32, 95% CI 0.01 to 7.61; 1 RCT; 73 women; <a href="./references#CD002120-fig-0010" title="">Analysis 1.3</a>). </p> <p>For irregular bleeding, the results were similar to the main analysis (RR 2.54, 95% CI 1.99 to 3.25; I² = 63%; 3 RCTs, 279 women; <a href="./references#CD002120-fig-0010" title="">Analysis 1.3</a>). </p> <p>The number of women with headaches almost doubled, suggesting that the effect might be higher than reported in the main analysis (RR 2.94, 95% CI 1.35 to 6.43; I² = 0%; 2 RCTs, 41 women; <a href="./references#CD002120-fig-0010" title="">Analysis 1.3</a>). </p> <p>The number of women with nausea increased by almost 100% from the main analysis (RR 2.89, 95% CI 1.18 to 7.05; I² = 34%; 3 RCTs, 346 women; <a href="./references#CD002120-fig-0010" title="">Analysis 1.3</a>). </p> <p>The two studies responsible for the increased risk of nausea and headache both compared norethisterone to placebo (<a href="./references#CD002120-bbs2-0009" title="HaradaT , MomoedaM , TerakawaN , TaketaniY , HoshiaiH . Evaluation of a low-dose oral contraceptive pill for primary dysmenorrhea: a placebo-controlled, double-blind, randomized trial. Fertility and Sterility2011;95(6):1928-31. ">Harada 2011</a>; <a href="./references#CD002120-bbs2-0010" title="HaradaT , MomoedaM . Evaluation of an ultra-low-dose oral contraceptive for dysmenorrhea: a placebo-controlled, double-blind, randomized trial. Fertility and Sterility2016;106(7):1807-14. [DOI: doi: 10.1016/j.fertnstert.2016.08.051.]">Harada 2016</a>). It is possible that the explanation for the increased risk evident in the sensitivity analysis is not due to risk of bias, but that this progestin has an increased risk of nausea and headache. </p> <p>Removing studies at unclear or high risk of allocation concealment for weight gain left no studies for re‐analysis. </p> </section> </section> <section id="CD002120-sec-0077"> <h4 class="title">2. Combined oral contraceptive pill versus another contraceptive pill</h4> <section id="CD002120-sec-0078"> <h5 class="title">Primary outcomes</h5> <section id="CD002120-sec-0079"> <h6 class="title">2.1 Pain scores</h6> <p>We divided the studies into the following subgroups, as combining them would not make biological sense. </p> <p> <ol id="CD002120-list-0012"> <li> <p>Continuous usage of OCP with no pause between the usual 28‐day period (and hence no withdrawal bleeding) compared to usual regimen of either seven or four days of pause between the 21 or 24 days of active hormone tablets </p> </li> <li> <p>Fourth‐ or third‐generation progestins compared with first‐ or second‐generation progestins</p> </li> <li> <p>EE 20 μg compared with EE 30 μg</p> </li> <li> <p>Dienogest compared to drospirenone (both considered fourth‐generation progestogens)</p> </li> </ol> </p> <p>See <a href="#CD002120-fig-0007">Figure 7</a>. </p> <div class="figure" id="CD002120-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Combined low‐dose OCP versus combined low‐dose OCP, outcome: 2.1 Pain score (continuous data)." data-id="CD002120-fig-0007" src="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-FIG-07.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Combined low‐dose OCP versus combined low‐dose OCP, outcome: 2.1 Pain score (continuous data). </p> </div> </div> </div> <section id="CD002120-sec-0080"> <p><b>2.1.1 Continuous use of oral contraceptive pill versus standard use of oral contraceptive pill</b></p> <p>Continuous usage of OCPs may reduce pain compared to standard usage (SMD −0.73, 95% CI −1.13 to −0.34; I² = 0%; 2 RCTs, 106 women; low‐quality evidence; <a href="./references#CD002120-fig-0017" title="">Analysis 2.1</a>). Both studies reported pain as a VAS score after treatment, but due to a large difference in SDs, we used an SMD. On a VAS scale (0 mm to 100 mm), it would be equal to a 7‐mm difference. </p> <p>This was supported by two additional RCTs that we did not include in the meta‐analysis due to technical issues, but pooled results found that continuous use reduced the number of days with pain by four (95% CI −5.7 to −2.3; 2 studies, 435 participants; meta‐analysis not reported; <a href="./references#CD002120-bbs2-0016" title="MomoedaM , KondoM , ElliesenJ , YasudaM , YamamotoS , HaradaT . Efficacy and safety of a flexible extended regimen of ethinylestradiol/drospirenone for the treatment of dysmenorrhea: a multicenter, randomized, open-label, active-controlled study. International Journal of Women's Health2017;2;9:295-305. [DOI: 10.2147/IJWH.S134576]">Momoeda 2017</a>; <a href="./references#CD002120-bbs2-0020" title="StrowitzkiT , KirschB , ElliesenJ . Efficacy of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen in women with moderate-to-severe primary dysmenorrhoea: an open-label, multicentre, randomised, controlled study. Journal of Family Planning and Reproductive Health Care2012;38(2):94-101. [DOI: 10.1136/jfprhc-2011-100225.]">Strowitzki 2012</a>). </p> <p>The studies used levonorgestrel (<a href="./references#CD002120-bbs2-0011" title="HaradaT , MomoedaM . Efficacy of cyclic and extended regimens of ethinylestradiol 0.02 mg-levonorgestrel 0.09 mg for dysmenorrhea: a placebo-controlled, double-blind, randomized trial. Reproductive Medicine and Biology2021;20(2):215-23. [DOI: 10.1002/rmb2.12373]">Harada 2021</a>), gestodene (<a href="./references#CD002120-bbs2-0006" title="DmitrovicR , KunselmanAR , LegroRS . Continuous compared with cyclic oral contraceptives for the treatment of primary dysmenorrhea: a randomized controlled trial. Obstetrics &amp; Gynecology2012;119(6):1143-50. ">Dmitrovic 2012</a>), and drospirenone (<a href="./references#CD002120-bbs2-0016" title="MomoedaM , KondoM , ElliesenJ , YasudaM , YamamotoS , HaradaT . Efficacy and safety of a flexible extended regimen of ethinylestradiol/drospirenone for the treatment of dysmenorrhea: a multicenter, randomized, open-label, active-controlled study. International Journal of Women's Health2017;2;9:295-305. [DOI: 10.2147/IJWH.S134576]">Momoeda 2017</a>; <a href="./references#CD002120-bbs2-0020" title="StrowitzkiT , KirschB , ElliesenJ . Efficacy of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen in women with moderate-to-severe primary dysmenorrhoea: an open-label, multicentre, randomised, controlled study. Journal of Family Planning and Reproductive Health Care2012;38(2):94-101. [DOI: 10.1136/jfprhc-2011-100225.]">Strowitzki 2012</a>) for 4.5 months to 6 months. In the case of bleeding spotting through three days, a four‐day pause was recommended in the continuous group of two of the trials (<a href="./references#CD002120-bbs2-0016" title="MomoedaM , KondoM , ElliesenJ , YasudaM , YamamotoS , HaradaT . Efficacy and safety of a flexible extended regimen of ethinylestradiol/drospirenone for the treatment of dysmenorrhea: a multicenter, randomized, open-label, active-controlled study. International Journal of Women's Health2017;2;9:295-305. [DOI: 10.2147/IJWH.S134576]">Momoeda 2017</a>; <a href="./references#CD002120-bbs2-0020" title="StrowitzkiT , KirschB , ElliesenJ . Efficacy of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen in women with moderate-to-severe primary dysmenorrhoea: an open-label, multicentre, randomised, controlled study. Journal of Family Planning and Reproductive Health Care2012;38(2):94-101. [DOI: 10.1136/jfprhc-2011-100225.]">Strowitzki 2012</a>). </p> </section> <section id="CD002120-sec-0081"> <p><b>2.1.2 First‐/second‐generation versus third‐/fourth‐generation progestins</b></p> <p>Only one study compared older generation (first/second) with newer (third/fourth) progestins (<a href="./references#CD002120-bbs2-0019" title="PetragliaF , ParkeS , SerraniM , MellingerU , RömerT . Estradiol valerate plus dienogest versus ethinylestradiol plus levonorgestrel for the treatment of primary dysmenorrhea. International Journal of Gynecology &amp; Obstetrics2014;125(3):270-4. [DOI: 10.1016/j.ijgo.2013.11.017]">Petraglia 2014</a>). The study compared dienogest with levonorgestrel, but we could not include the data in the meta‐analysis, as it only reported mean change and not a post‐treatment score. There was no evidence of a difference between the two groups. The fourth‐generation progestin group reported 10.6 fewer days with pain versus 10.0 days for the second‐generation progestin group (444 women; P = 0.50). </p> </section> <section id="CD002120-sec-0082"> <p><b>2.1.3 Ethinylestradiol 20 μg versus ethinylestradiol 30 μg</b></p> <p>One study compared EE 20 μg with EE 30 μg; both groups received drospirenone (<a href="./references#CD002120-bbs2-0014" title="MomoedaM , HayakawaM , ShimazakiY , MizunumaH , TaketaniY . Does the presence of coexisting diseases modulate the effectiveness of a low-dose estrogen/progestin, ethinylestradiol/drospirenone combination tablet in dysmenorrhea? Reanalysis of two randomized studies in Japanese women. International Journal of Women's Health2014;6:989-98. MomoedaM , MizunumaH , TaketaniY . Long term efficacy and safety of drospirenone/ethinylestradiol combination (YAZ) tablets for patients with dysmenorrhea: Shinryo to Shinyaku. Medical Consult and New Remedies [Japanese version]2010;47:1003-15. ">Momoeda 2010a</a>). The study only reported mean change, and we could not include the data in the meta‐analysis because we calculated SMD. The mean changes were −2.4 for the EE 20 μg group and −2.3 for the EE 30 μg group (332 women; P = 0.67). </p> </section> <section id="CD002120-sec-0083"> <p><b>2.1.4 Dienogest versus drospirenone</b></p> <p>There was insufficient evidence to determine a difference between dienogest and drospireinone (MD −0.64, 95% CI −1.39 to 0.11; 1 RCT, 66 women; <a href="./references#CD002120-bbs2-0021" title="UysalG , AkkayaH , CagliF , TutusS , TayyarAT . A comparison of two different oral contraceptives in patients with severe primary dysmenorrhoea. Journal of Obstetrics and Gynaecology2018;38(6):828-32. [DOI: 10.1080/01443615.2017.1410533]">Uysal 2018</a>). </p> </section> </section> <section id="CD002120-sec-0084"> <h6 class="title">2.2 Pain improvement</h6> <section id="CD002120-sec-0085"> <p><b>2.2.1 Ethinylestradiol 20 μg versus ethinylestradiol 30 μg</b></p> <p>There was insufficient evidence to determine a difference between EE 20 μg and EE 30 μg (RR 1.06, 95% CI 0.65 to 1.74; 1 RCT, 326 participants; <a href="./references#CD002120-fig-0018" title="">Analysis 2.2</a>). There was insufficient evidence to determine a difference between third/fourth‐generation progestins compared to first/second‐generation progestins (RR 0.99, 95% CI 0.93 to 1.05; 1 RCT, 178 participants; <a href="./references#CD002120-fig-0018" title="">Analysis 2.2</a>), in this case a comparison between drospirenone and chlormadinone. </p> </section> </section> <section id="CD002120-sec-0086"> <h6 class="title">2.3 Adverse events</h6> <section id="CD002120-sec-0087"> <p><b>2.3.1 Continuous use of oral contraceptive pill versus standard usage of oral contraceptive pill</b></p> <p>We only pooled the adverse events for the subgroup of studies comparing continuous regimens of OCPs with standard regimens. The continuous regimen may slightly increase the occurrence of any adverse events compared to standard regimen (RR 1.11, 95% CI 1.01 to 1.22; I² = 76%; 3 RCTs, 602 women; low‐quality evidence; <a href="./references#CD002120-fig-0019" title="">Analysis 2.3</a>). Due to substantial heterogeneity, this result has to be interpreted with caution. We decided to keep the analysis since all studies estimated the same direction of effect. It is uncertain whether there was a difference between groups in serious adverse events (RR 0.34, 95% CI 0.01 to 8.24; 1 RCT, 212 women; low‐quality evidence; <a href="./references#CD002120-fig-0019" title="">Analysis 2.3</a>); headaches (RR 0.94, 95% CI 0.50 to 1.76; I² = 0%; 2 RCTs, 435 women; low‐quality evidence; <a href="./references#CD002120-fig-0019" title="">Analysis 2.3</a>); or nausea (RR 1.08, 95% CI 0.51 to 2.30; I² = 23%; 2 RCTs, 435 women; low‐quality evidence; <a href="./references#CD002120-fig-0019" title="">Analysis 2.3</a>). The continuous regimen probably increases the risk of irregular bleeding (RR 1.38, 95% CI 1.14 to 1.69; I² = 3%; 2 RCT, 379 women; moderate‐quality evidence; <a href="./references#CD002120-fig-0019" title="">Analysis 2.3</a>). </p> <p><a href="./references#CD002120-bbs2-0006" title="DmitrovicR , KunselmanAR , LegroRS . Continuous compared with cyclic oral contraceptives for the treatment of primary dysmenorrhea: a randomized controlled trial. Obstetrics &amp; Gynecology2012;119(6):1143-50. ">Dmitrovic 2012</a> found increased weight gain in the continuous group of 2.3 kg (95% CI 0.8 to 3.8) compared to placebo, but could not be included in the meta‐analysis. The study only randomised 38 women but used effective blinding. The two other studies did not report weight changes after treatment. </p> <p><a href="./references#CD002120-bbs2-0006" title="DmitrovicR , KunselmanAR , LegroRS . Continuous compared with cyclic oral contraceptives for the treatment of primary dysmenorrhea: a randomized controlled trial. Obstetrics &amp; Gynecology2012;119(6):1143-50. ">Dmitrovic 2012</a> found that women in the continuous group reported almost twice as many days with bleeding. It was reported as a continuous outcome and, therefore, could not be included in our meta‐analysis. The study did not specify whether women should pause hormone treatment in cases of spotting. </p> </section> </section> </section> <section id="CD002120-sec-0088"> <h5 class="title">Secondary outcomes</h5> <section id="CD002120-sec-0089"> <h6 class="title">2.4 Additional analgesia</h6> <section id="CD002120-sec-0090"> <p><b>2.4.1 Fourth/third generation versus first/second</b></p> <p>One study compared additional analgesia as a continuous outcome (number of tablets); but there was insufficient evidence to determine an effect (MD 1.10, 95% CI −2.12 to 4.32; 1 RCT, 444 participants; <a href="./references#CD002120-fig-0020" title="">Analysis 2.4</a>). </p> </section> </section> <section id="CD002120-sec-0091"> <h6 class="title">2.5 Absence from school or work</h6> <section id="CD002120-sec-0092"> <p><b>2.5.1 Fourth/third generation versus first/second</b></p> <p>One study reported absence from school, but there was insufficient evidence to determine an effect (RR 1.12, 95% CI 0.64 to 1.99; 1 RCT, 445 women; very low‐quality evidence; <a href="./references#CD002120-fig-0021" title="">Analysis 2.5</a>). </p> </section> </section> <section id="CD002120-sec-0093"> <h6 class="title">2.6 Withdrawals from treatment</h6> <section id="CD002120-sec-0094"> <p><b>2.6.1 Continuous versus standard regimen</b></p> <p>Three studies reported withdrawals but were very inconsistent (I² = 72%). <a href="./references#CD002120-bbs2-0006" title="DmitrovicR , KunselmanAR , LegroRS . Continuous compared with cyclic oral contraceptives for the treatment of primary dysmenorrhea: a randomized controlled trial. Obstetrics &amp; Gynecology2012;119(6):1143-50. ">Dmitrovic 2012</a> included only 38 participants and had estimated the RR as 1.25 but with broad 95% CIs (0.40 to 3.95). <a href="./references#CD002120-bbs2-0016" title="MomoedaM , KondoM , ElliesenJ , YasudaM , YamamotoS , HaradaT . Efficacy and safety of a flexible extended regimen of ethinylestradiol/drospirenone for the treatment of dysmenorrhea: a multicenter, randomized, open-label, active-controlled study. International Journal of Women's Health2017;2;9:295-305. [DOI: 10.2147/IJWH.S134576]">Momoeda 2017</a> included 212 participants and found many more dropouts in the standard regimen group (RR 0.31, 95% CI 0.14 to 0.69). This study was not blinded and was at high risk of performance bias. <a href="./references#CD002120-bbs2-0011" title="HaradaT , MomoedaM . Efficacy of cyclic and extended regimens of ethinylestradiol 0.02 mg-levonorgestrel 0.09 mg for dysmenorrhea: a placebo-controlled, double-blind, randomized trial. Reproductive Medicine and Biology2021;20(2):215-23. [DOI: 10.1002/rmb2.12373]">Harada 2021</a> included 2212 participants and estimated the RR as 1.15. Due to heterogeneity, we decided not to pool the data. A random‐effects model would give too much weight to the small study. </p> </section> <section id="CD002120-sec-0095"> <p><b>2.6.2 Fourth/third generation versus first/second</b></p> <p>Only one study reported data, which was insufficient to estimate dropouts with certainty (RR 0.80, 95% CI 0.43 to 1.47; 1 RCT, 464 women; <a href="./references#CD002120-fig-0015" title="">Analysis 1.8</a>). </p> </section> <section id="CD002120-sec-0096"> <p><b>2.6.3 Ethinylestradiol 20 μg versus ethinylestradiol 30 μg</b></p> <p>One study compared EE 20 μg with EE 30 μg (both groups received drospirenone) and reported an increased number of dropouts in the EE 20 μg group (RR 2.71, 95% CI 1.14 to 6.44; 1 RCT, 420 women; <a href="./references#CD002120-fig-0022" title="">Analysis 2.6</a>). The data were published on <a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a> and were not consistent. We contacted the study author for clarification, but have not yet received a response to our follow‐up questions. </p> </section> </section> <section id="CD002120-sec-0097"> <h6 class="title">2.7 Withdrawals from treatment due to adverse effects</h6> <section id="CD002120-sec-0098"> <p><b>2.7.1 Continuous versus standard regimen</b></p> <p>Fewer women seemed to withdraw from the continuous regimen group compared to the standard regimen (RR 0.19, 95% CI 0.06 to 0.63; I² = 0; 3 RCTs, 414 women; <a href="./references#CD002120-fig-0023" title="">Analysis 2.7</a>). However, the estimate was contradictory to withdrawals for any reason (<a href="./references#CD002120-fig-0022" title="">Analysis 2.6</a>). </p> </section> <section id="CD002120-sec-0099"> <p><b>2.7.2 Fourth/third generation versus first/second</b></p> <p>Only one study reported data, which was insufficient to estimate dropouts with certainty (RR 0.98, 95% CI 0.29 to 3.35; 1 RCT, 464 women; <a href="./references#CD002120-fig-0023" title="">Analysis 2.7</a>). </p> </section> <section id="CD002120-sec-0100"> <p><b>2.7.3 Ethinylestradiol 20 μg versus ethinylestradiol 30 μg</b></p> <p>One trial reported data, which was insufficient to estimate dropouts with certainty (RR 1.72, 95% CI 0.54 to 5.48; 1 RCT, 326 women; <a href="./references#CD002120-fig-0023" title="">Analysis 2.7</a>). </p> </section> </section> </section> <section id="CD002120-sec-0101"> <h5 class="title">Sensitivity analyses</h5> <p>There were too few studies to conduct any sensitivity analyses.</p> </section> </section> <section id="CD002120-sec-0102"> <h4 class="title">3. Combined oral contraceptive pill versus non‐steroidal anti‐inflammatory drugs</h4> <section id="CD002120-sec-0103"> <h5 class="title">Primary outcomes</h5> <section id="CD002120-sec-0104"> <h6 class="title">3.1 Pain scores</h6> <p>Only one trial compared OCPs (desogestrel 0.15 mg/EE 30 μg) to NSAIDs (mefenamic acid), measured using a VAS. We are uncertain if OCPs are better than NSAIDs for relieving pain (MD −0.30, 95% CI −5.43 to 4.83; 1 RCT, 91 women; low‐quality evidence; <a href="./references#CD002120-fig-0024" title="">Analysis 3.1</a>). </p> <p>The study reported no other outcomes relevant to our review.</p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD002120-sec-0105" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD002120-sec-0105"></div> <section id="CD002120-sec-0106"> <h3 class="title" id="CD002120-sec-0106">Summary of main results</h3> <p>We included 21 RCTs in this updated review; 11 compared different OCP preparations with placebo only, eight compared different preparations with each other, one compared different OCPs with each other and placebo (three‐armed study), and one compared OCPs with NSAIDs. </p> <p>OCPs are more effective than placebo at treating dysmenorrhoea. However, they have adverse effects in the form of irregular bleeding, headache, and nausea. We did not cover long‐term adverse effects (over six months) in this review due to lack of long‐term RCTs. See <a href="./full#CD002120-tbl-0001">summary of findings Table 1</a>. </p> <p>Continuous use of OCPs without pause compared to the standard 21‐day treatment/seven‐day pause regimen may be superior at treating dysmenorrhoea, but little is known about adverse effects in both the short‐ and long‐term. One study including 38 women indicated weight gain in the continuous group. See <a href="./full#CD002120-tbl-0002">summary of findings Table 2</a>. </p> <p>We found no differences between the different OCPs.</p> <p>There was insufficient evidence to estimate the effects of NSAIDs compared to OCPs.</p> </section> <section id="CD002120-sec-0107"> <h3 class="title" id="CD002120-sec-0107">Overall completeness and applicability of evidence</h3> <p>OCPs are widely advocated as standard treatment for women with primary dysmenorrhoea, which, until recently, was based on scant evidence. This review confirmed that OCPs are beneficial for pain due to primary dysmenorrhoea, which has also been found in observational studies (<a href="./references#CD002120-bbs2-0056" title="MilsomI , AnderschB . Effect of various oral contraceptive combinations on dysmenorrhea. Gynaecologic and Obstetric Investigation1984;17:284-92.">Milsom 1984</a>; <a href="./references#CD002120-bbs2-0057" title="MilsomI , SundellG , AnderschB . The influence of different combined oral contraceptives on the prevalence and severity of dysmenorrhea. Contraception1990;42(5):497-506.">Milsom 1990</a>). </p> <p>Inclusion criteria and treatment regimens seemed relevant. Better outcome reporting and longer follow‐up could give more relevant information. </p> <p>Continuous usage of OCPs is also being advocated. Even though this review confirmed that OCPs are effective, it also highlighted the lack of data on safety. This is due to poor reporting, but also limited follow‐up. </p> <p>Another issue that needs to be considered is that the use of OCPs as treatment for dysmenorrhoea does not just depend on their efficacy, but also the suitability of OCPs for the woman. If a woman wants to become pregnant or has contraindications to the OCP, then the OCP would be an unsuitable treatment option at that time. </p> <p>There are also difficulties in extrapolating the results of this review to modern‐day populations, as some of the older included trials used higher levels of oestrogen than typically used today. However, the results from these older studies do not seem to differ from the newer studies. </p> </section> <section id="CD002120-sec-0108"> <h3 class="title" id="CD002120-sec-0108">Quality of the evidence</h3> <p>Due to poor reporting, many bias domains were unclear. Five studies were not blinded, which can cause bias especially when the outcome was subjective. </p> <p>However, the studies that provided data for pain score comparing OCP with placebo or no treatment were at low or unclear risk of blinding (selection bias). Most studies were sponsored by drug manufacturers but aside from this there was no risk of bias, and no imprecision, substantial heterogeneity, or indirectness and therefore pain score was not downgraded and remained as high quality. Two trials could not be included because they only reported mean change, but the results were similar, and supported the conclusion of the meta‐analysis. </p> <p>Pain improvement as a dichotomous outcome was downgraded two levels for inconsistency and indirectness, and the quality of evidence was therefore assessed as low. </p> <p>For the comparison of continuous contraceptives with standard regimen, the studies were unblinded and, therefore, we downgraded the evidence as participants could easily guess allocation since one group would get withdrawal bleeding after 21 days. We also downgraded for imprecision, which resulted in low‐quality evidence. </p> <p>The manufacturer of the contraceptive being investigated funded 11/21 studies; this type of funding has been linked to increased effect estimates (<a href="./references#CD002120-bbs2-0055" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. Art. No: MR000033. [DOI: 10.1002/14651858.MR000033.pub3]">Lundh 2017</a>). Another seven trials had unclear funding; only three had independent funding. </p> </section> <section id="CD002120-sec-0109"> <h3 class="title" id="CD002120-sec-0109">Potential biases in the review process</h3> <p>There were methodological problems associated with quantifying and grading the pain of dysmenorrhoea. Assessment instruments used in quantifying dysmenorrhoea are based on a woman's self‐report and as such, are subject to obvious bias. In addition, all the trials categorised pain using different scales, which may be a significant source of heterogeneity in this review. We attempted to identify and include all relevant studies through database and handsearching. Our protocol did not specify withdrawal from study and withdrawal due to adverse events, but we consider they offer a better understanding of adverse events, which were initially specified. </p> </section> <section id="CD002120-sec-0110"> <h3 class="title" id="CD002120-sec-0110">Agreements and disagreements with other studies or reviews</h3> <p>Very few systematic reviews have been published on contraceptives for primary dysmenorrhoea since the last publication of this review. OCPs are widely used, even though the previous version of this review did not find an effect (<a href="./references#CD002120-bbs2-0065" title="WongCL , FarquharC , RobertsH , ProctorM . Oral contraceptive pill for primary dysmenorrhoea. Cochrane Database of Systematic Reviews2009, Issue 4. Art. No: CD002120. [DOI: 10.1002/14651858.CD002120.pub3]">Wong 2009</a>). Since the previous version, more studies have been published that support the use of contraceptives. In this review, we also included the continuous use of combined OCP, which seems to be even more efficient than the traditional regimen. This makes biological sense, as bleeding will cause uterine contractions, which can cause pain. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD002120-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/urn:x-wiley:14651858:media:CD002120:CD002120-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA flowchart." data-id="CD002120-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_t/tCD002120-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA flowchart.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/full#CD002120-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002120-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/urn:x-wiley:14651858:media:CD002120:CD002120-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Review authors' judgements about each risk of bias, presented as percentages across all included studies." data-id="CD002120-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_t/tCD002120-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Review authors' judgements about each risk of bias, presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/full#CD002120-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002120-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/urn:x-wiley:14651858:media:CD002120:CD002120-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Review authors' judgements about each risk of bias for each included study." data-id="CD002120-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_t/tCD002120-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Review authors' judgements about each risk of bias for each included study.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/full#CD002120-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002120-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/urn:x-wiley:14651858:media:CD002120:CD002120-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Combined OCP versus placebo or no treatment, outcome: 1.1 Pain score (continuous data)." data-id="CD002120-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_t/tCD002120-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Combined OCP versus placebo or no treatment, outcome: 1.1 Pain score (continuous data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/full#CD002120-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002120-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/urn:x-wiley:14651858:media:CD002120:CD002120-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Combined OCP versus placebo or no treatment, outcome: 1.2 Pain improvement." data-id="CD002120-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_t/tCD002120-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Combined OCP versus placebo or no treatment, outcome: 1.2 Pain improvement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/full#CD002120-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002120-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/urn:x-wiley:14651858:media:CD002120:CD002120-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Combined OCP versus placebo or no treatment, outcome: 1.3 Adverse events." data-id="CD002120-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_t/tCD002120-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Combined OCP versus placebo or no treatment, outcome: 1.3 Adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/full#CD002120-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002120-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/urn:x-wiley:14651858:media:CD002120:CD002120-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Combined low‐dose OCP versus combined low‐dose OCP, outcome: 2.1 Pain score (continuous data)." data-id="CD002120-fig-0007" src="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-FIG-07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_t/tCD002120-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Combined low‐dose OCP versus combined low‐dose OCP, outcome: 2.1 Pain score (continuous data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/full#CD002120-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-FIG-07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002120-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/urn:x-wiley:14651858:media:CD002120:CD002120-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Combined OCP versus placebo or no treatment, Outcome 1: Pain score (continuous data)" data-id="CD002120-fig-0008" src="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_t/tCD002120-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Combined OCP versus placebo or no treatment, Outcome 1: Pain score (continuous data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/references#CD002120-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002120-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/urn:x-wiley:14651858:media:CD002120:CD002120-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Combined OCP versus placebo or no treatment, Outcome 2: Pain improvement" data-id="CD002120-fig-0009" src="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_t/tCD002120-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Combined OCP versus placebo or no treatment, Outcome 2: Pain improvement</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/references#CD002120-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002120-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/urn:x-wiley:14651858:media:CD002120:CD002120-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Combined OCP versus placebo or no treatment, Outcome 3: Adverse events" data-id="CD002120-fig-0010" src="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_t/tCD002120-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Combined OCP versus placebo or no treatment, Outcome 3: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/references#CD002120-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002120-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/urn:x-wiley:14651858:media:CD002120:CD002120-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Combined OCP versus placebo or no treatment, Outcome 4: Additional analgesia required" data-id="CD002120-fig-0011" src="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_t/tCD002120-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Combined OCP versus placebo or no treatment, Outcome 4: Additional analgesia required </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/references#CD002120-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002120-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/urn:x-wiley:14651858:media:CD002120:CD002120-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Combined OCP versus placebo or no treatment, Outcome 5: Additional analgesia (continuous data)" data-id="CD002120-fig-0012" src="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_t/tCD002120-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Combined OCP versus placebo or no treatment, Outcome 5: Additional analgesia (continuous data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/references#CD002120-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002120-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/urn:x-wiley:14651858:media:CD002120:CD002120-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Combined OCP versus placebo or no treatment, Outcome 6: Absence from school or work" data-id="CD002120-fig-0013" src="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_t/tCD002120-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Combined OCP versus placebo or no treatment, Outcome 6: Absence from school or work </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/references#CD002120-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002120-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/urn:x-wiley:14651858:media:CD002120:CD002120-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Combined OCP versus placebo or no treatment, Outcome 7: Absence from school or work (continuous)" data-id="CD002120-fig-0014" src="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_t/tCD002120-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Combined OCP versus placebo or no treatment, Outcome 7: Absence from school or work (continuous) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/references#CD002120-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002120-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/urn:x-wiley:14651858:media:CD002120:CD002120-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Combined OCP versus placebo or no treatment, Outcome 8: Withdrawals from treatment" data-id="CD002120-fig-0015" src="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_t/tCD002120-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Combined OCP versus placebo or no treatment, Outcome 8: Withdrawals from treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/references#CD002120-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002120-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/urn:x-wiley:14651858:media:CD002120:CD002120-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Combined OCP versus placebo or no treatment, Outcome 9: Withdrawals from treatment due to adverse events" data-id="CD002120-fig-0016" src="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_t/tCD002120-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Combined OCP versus placebo or no treatment, Outcome 9: Withdrawals from treatment due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/references#CD002120-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002120-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/urn:x-wiley:14651858:media:CD002120:CD002120-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Combined low dose (ethinylestradiol (EE) 20–30 μg) OCP versus another combined low dose (EE 20–30 μg) OCP, Outcome 1: Pain score (continuous data)" data-id="CD002120-fig-0017" src="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_t/tCD002120-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Combined low dose (ethinylestradiol (EE) 20–30 μg) OCP versus another combined low dose (EE 20–30 μg) OCP, Outcome 1: Pain score (continuous data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/references#CD002120-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002120-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/urn:x-wiley:14651858:media:CD002120:CD002120-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Combined low dose (ethinylestradiol (EE) 20–30 μg) OCP versus another combined low dose (EE 20–30 μg) OCP, Outcome 2: Pain improvement" data-id="CD002120-fig-0018" src="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_t/tCD002120-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Combined low dose (ethinylestradiol (EE) 20–30 μg) OCP versus another combined low dose (EE 20–30 μg) OCP, Outcome 2: Pain improvement </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/references#CD002120-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002120-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/urn:x-wiley:14651858:media:CD002120:CD002120-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Combined low dose (ethinylestradiol (EE) 20–30 μg) OCP versus another combined low dose (EE 20–30 μg) OCP, Outcome 3: Adverse events for continuous vs standard regimen OCP" data-id="CD002120-fig-0019" src="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_t/tCD002120-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Combined low dose (ethinylestradiol (EE) 20–30 μg) OCP versus another combined low dose (EE 20–30 μg) OCP, Outcome 3: Adverse events for continuous vs standard regimen OCP </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/references#CD002120-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002120-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/urn:x-wiley:14651858:media:CD002120:CD002120-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Combined low dose (ethinylestradiol (EE) 20–30 μg) OCP versus another combined low dose (EE 20–30 μg) OCP, Outcome 4: Additional analgesia (continuous data)" data-id="CD002120-fig-0020" src="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_t/tCD002120-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Combined low dose (ethinylestradiol (EE) 20–30 μg) OCP versus another combined low dose (EE 20–30 μg) OCP, Outcome 4: Additional analgesia (continuous data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/references#CD002120-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002120-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/urn:x-wiley:14651858:media:CD002120:CD002120-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Combined low dose (ethinylestradiol (EE) 20–30 μg) OCP versus another combined low dose (EE 20–30 μg) OCP, Outcome 5: Absence from school or work" data-id="CD002120-fig-0021" src="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_t/tCD002120-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Combined low dose (ethinylestradiol (EE) 20–30 μg) OCP versus another combined low dose (EE 20–30 μg) OCP, Outcome 5: Absence from school or work </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/references#CD002120-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002120-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/urn:x-wiley:14651858:media:CD002120:CD002120-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Combined low dose (ethinylestradiol (EE) 20–30 μg) OCP versus another combined low dose (EE 20–30 μg) OCP, Outcome 6: Withdrawals from treatment" data-id="CD002120-fig-0022" src="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_t/tCD002120-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Combined low dose (ethinylestradiol (EE) 20–30 μg) OCP versus another combined low dose (EE 20–30 μg) OCP, Outcome 6: Withdrawals from treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/references#CD002120-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002120-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/urn:x-wiley:14651858:media:CD002120:CD002120-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Combined low dose (ethinylestradiol (EE) 20–30 μg) OCP versus another combined low dose (EE 20–30 μg) OCP, Outcome 7: Withdrawals from treatment due to adverse events" data-id="CD002120-fig-0023" src="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_t/tCD002120-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Combined low dose (ethinylestradiol (EE) 20–30 μg) OCP versus another combined low dose (EE 20–30 μg) OCP, Outcome 7: Withdrawals from treatment due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/references#CD002120-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002120-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/urn:x-wiley:14651858:media:CD002120:CD002120-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Combined OCP versus non‐steroidal anti‐inflammatory drug (NSAID), Outcome 1: Pain score (continuous data)" data-id="CD002120-fig-0024" src="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_t/tCD002120-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Combined OCP versus non‐steroidal anti‐inflammatory drug (NSAID), Outcome 1: Pain score (continuous data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/references#CD002120-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/media/CDSR/CD002120/image_n/nCD002120-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD002120-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Combined OCP compared to placebo or no treatment for primary dysmenorrhoea</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Combined OCP compared to placebo or no treatment for primary dysmenorrhoea</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with primary dysmenorrhoea<br/><b>Setting:</b> medical centres and clinics<br/><b>Intervention:</b> combined OCP<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Quality</b> of the evidence<br/>(GRADE) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with combined OCP</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Pain score</b> </p> <p>(assessed with Total Dysmenorrhoea Score; 0–6; lower score is better; and Moos Menstrual Distress Questionnaire pain subscale; 0–24; lower score is better) </p> <p><i>follow‐up range 3–4 months</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The standardised mean pain score was <b>0.58 points lower</b><br/>(0.74 lower to 0.41 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>588<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The change in standardised mean difference represents an improvement of 0.8 point on the Total Dysmenorrhoea Score (0–6) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Pain improvement</b> </p> <p>(assessed as improvement from 1 major category to next)</p> <p><i>follow‐up range 1–4 months</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>284 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>469 per 1000<br/>(367 to 597) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.65</b><br/>(1.29 to 2.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>717<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Any adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>590 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>773 per 1000<br/>(708 to 855) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.31</b><br/>(1.20 to 1.43) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1025<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> <p><i>follow‐up range 3–4 months</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000<br/>(5 to 68) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.77</b><br/>(0.49 to 6.43) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>512<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Irregular bleeding</b> </p> <p><i>follow‐up range 3–4 months</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>182 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>479 per 1000<br/>(385 to 598) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.63</b><br/>(2.11 to 3.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1025<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Headaches</b> </p> <p><i>follow‐up range 3–4 months</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>174 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>262 per 1000<br/>(193 to 354) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.51</b><br/>(1.11 to 2.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>656<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Nausea</b> </p> <p><i>follow‐up range 3–4 months</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>95 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>156 per 1000<br/>(111 to 219) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.64</b><br/>(1.17 to 2.30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>948<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weight gain</b> </p> <p><i>3‐month follow‐up</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>158 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>289 per 1000<br/>(118 to 703) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.83</b><br/>(0.75 to 4.45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Requirement for additional medication</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>377 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>237 per 1000<br/>(151 to 369) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.63</b><br/>(0.40 to 0.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>f,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Absence from work or school</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>362 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>228 per 1000<br/>(112 to 351) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.63</b><br/>(0.41 to 0.97) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>f,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>OCP:</b> oral contraceptive pill; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Most studies sponsored by industry, but other risk of bias domains were mostly low, so overall, this was considered not serious.<br/><sup>b</sup>The I² was 45%, but we did not downgrade.<br/><sup>c</sup>Downgraded one level for inconsistency – I² above 50%.<br/><sup>d</sup>Downgraded one level for indirectness – 5 studies from the 1960/1970s that used drugs that are not available today. The reports contained very little information on risk of bias; combined with some imprecision, we decided to downgrade one level.<br/><sup>e</sup>Downgraded two levels for imprecision – wide confidence intervals.<br/><sup>f</sup>Downgraded one level due to some imprecision and some heterogeneity.<br/><sup>g</sup>Downgraded one level due to imprecision and few events.<br/><sup>h</sup>Downgraded one level due to risk of bias and concerns of indirectness. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Combined OCP compared to placebo or no treatment for primary dysmenorrhoea</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/full#CD002120-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002120-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Combined low‐dose OCP compared to another combined low‐dose OCP for primary dysmenorrhoea</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Combined low‐dose OCP compared to another combined low‐dose OCP for primary dysmenorrhoea</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with primary dysmenorrhoea<br/><b>Setting:</b> medical centres and clinics<br/><b>Intervention:</b> combined low‐dose OCP<br/><b>Comparison:</b> different combined low‐dose OCP </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Quality</b> of the evidence<br/>(GRADE) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with standard combined‐low‐dose OCP</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with experimental combined low‐dose OCP</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Pain score</b> </p> <p>(assessed with VAS; 0 to 100; lower score is better)</p> <p><i>follow‐up range 4–6 months</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The standardised mean pain score in the continuous regimen group was <b>0.73 points lower</b><br/>(1.13 lower to 0.34 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The change in SMD represented an improvement of 4 to 18 point on a VAS scale (0–100)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pain improvement</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EE 20 μg vs EE 30 μg</p> <p><i>6‐month follow‐up</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>259 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>275 per 1000<br/>(169 to 251) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.06</b><br/>(0.65 to 1.74) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>326<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4th/3rd vs 1st/2nd generation</p> <p><i>6‐month follow‐up</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>966 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>957 per 1000<br/>(899 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.99</b><br/>(0.93 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse events</b> for continuous vs standard regimen OCP </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adverse events</b> </p> <p><i>follow‐up range 4–6 months</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>652 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>724 per 1000<br/>(659 to 795) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.11</b><br/>(1.01 to 1.22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>602<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> <p><i>6‐month follow‐up</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000<br/>(0 to 77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.34</b><br/>(0.01 to 8.24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>212<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Irregular bleeding</b> </p> <p><i>follow‐up range 4–6 months</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>330 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>455 per 1000<br/>(376 to 557) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.38</b><br/>(1.14 to 1.69) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>379<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Headaches</b> </p> <p><i>follow‐up range 4–6 months</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>84 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>79 per 1000<br/>(42 to 147) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.94</b><br/>(0.50 to 1.76) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>435<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nausea</b><br/><i>follow‐up range 4–6 months</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 per 1000<br/>(28 to 128) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b><br/>(0.51 to 2.30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>435<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study assessed vomiting, which we interpreted as a proxy for nausea.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Weight gain</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported in any study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Requirement for additional medication</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported in any study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Absence from work or school</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>91 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>102 per 1000<br/>(58 to 181) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b><br/>(0.64 to 1.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>445<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>EE:</b> ethinylestradiol; <b>OCP:</b> oral contraceptive pill; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference; <b>VAS:</b> Visual Analogue Scale. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for risk of bias – studies not blinded, which is also difficult as vaginal bleeding should lead to pause in the continuous group<br/><sup>b</sup>Downgraded one level for imprecision – wide confidence intervals or few included participants<br/><sup>c</sup>Downgraded one level for heterogeneity – I² above 50%<br/><sup>d</sup>Downgraded two levels for imprecision – wide confidence intervals </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Combined low‐dose OCP compared to another combined low‐dose OCP for primary dysmenorrhoea</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/full#CD002120-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002120-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">NSAID compared to combined OCP for primary dysmenorrhoea</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>NSAID compared to combined OCP for primary dysmenorrhoea</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> women with primary dysmenorrhoea<br/><b>Setting:</b> medical centre<br/><b>Intervention:</b> NSAID<br/><b>Comparison:</b> combined OCP </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Quality</b> of the evidence<br/>(GRADE) </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with combined OCP</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with NSAIDs</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Pain score</b> </p> <p>(measured on VAS; 0–100; lower score is better)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain score in the combined OCP group was 35</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain score in the NSAID group was 0.30 points lower (5.43 lower to 4.83 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Pain improvement</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported in any study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported in any study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported in any study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Irregular bleeding</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported in any study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Headaches</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported in any study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nausea</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported in any study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weight gain</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported in any study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Requirement for additional medication</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported in any study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Absence from work or school</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported in any study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>NSAID:</b> non‐steroidal anti‐inflammatory drug; <b>OCP:</b> oral contraceptive pill; <b>RCT:</b> randomised controlled trial; <b>VAS:</b> Visual Analogue Scale. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for imprecision – wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">NSAID compared to combined OCP for primary dysmenorrhoea</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/full#CD002120-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002120-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Combined OCP versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Pain score (continuous data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>588</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.58 [‐0.74, ‐0.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Low‐dose (20–30 μg) oestrogen and 1st/2nd‐generation progestin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>377</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.53 [‐0.75, ‐0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Low‐dose (20–30 μg) oestrogen and 3rd/4th‐generation progestin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.65 [‐0.92, ‐0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Pain improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>717</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [1.29, 2.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Low‐dose (20–30 μg) oestrogen and 1st/2nd‐generation progestin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.98, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Low‐dose (20–30 μg) oestrogen and 3rd‐generation progestin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.15 [1.35, 12.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 Medium‐dose (30–100 μg) oestrogen and 1st/2nd‐generation progestin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>438</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [1.13, 2.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Any adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1025</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [1.20, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [0.49, 6.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 Irregular bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1025</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.63 [2.11, 3.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.4 Headaches</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>656</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [1.11, 2.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.5 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>948</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [1.17, 2.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.6 Weight gain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [0.75, 4.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Additional analgesia required <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.40, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Low‐dose (20–30 μg) oestrogen and 1st/2nd‐generation progestin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.36, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Medium‐dose (30–100 μg) oestrogen and 1st/2nd‐generation progestin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.25, 2.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Additional analgesia (continuous data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.11 [‐3.09, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Absence from school or work <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.41, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Low‐dose (20–30 μg) oestrogen and 1st/2nd‐generation progestin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Medium‐dose (30–100 μg) oestrogen and 1st/2nd‐generation progestin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.42, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Absence from school or work (continuous) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.92 [‐3.14, ‐0.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Withdrawals from treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.71, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Low‐dose (20–30 μg) oestrogen and 1st/2nd‐generation progestin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>668</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.60, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Low‐dose (20–30 μg) oestrogen and 3rd‐generation progestin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.68, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Withdrawals from treatment due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>928</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.64, 2.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Low‐dose (20–30 μg) oestrogen and 1st/2nd‐generation progestin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>526</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.55, 2.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Low‐dose (20–30 μg) oestrogen and 3rd‐generation progestin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>402</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.37, 5.35]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Combined OCP versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/references#CD002120-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002120-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Combined low dose (ethinylestradiol (EE) 20–30 μg) OCP versus another combined low dose (EE 20–30 μg) OCP</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Pain score (continuous data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Continuous vs standard regimen OCP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.73 [‐1.13, ‐0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Dienogest vs drospirenone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐0.89, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Pain improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 EE 20 μg vs EE 30 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.65, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 4th/3rd vs 1st/2nd generation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.93, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Adverse events for continuous vs standard regimen OCP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Any adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [1.01, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.3 Irregular bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [1.14, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.4 Headaches</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>435</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.50, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.5 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>435</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.51, 2.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Additional analgesia (continuous data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [‐2.12, 4.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 4th/3rd generation vs 1st/2nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [‐2.12, 4.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Absence from school or work <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.64, 1.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 4th/3rd generation versus 1st/2nd</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.64, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Withdrawals from treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 Continuous vs standard regimen OCP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>422</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.43, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.2 4th/3rd vs 1st/2nd generation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>464</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.43, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.3 EE 20 μg vs EE 30 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.71 [1.14, 6.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Withdrawals from treatment due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 Continuous vs standard regimen OCP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.06, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.2 4th/3rd vs 1st/2nd generation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>464</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.29, 3.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.3 EE 20 μg vs EE 30 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [0.54, 5.48]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Combined low dose (ethinylestradiol (EE) 20–30 μg) OCP versus another combined low dose (EE 20–30 μg) OCP</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/references#CD002120-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002120-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Combined OCP versus non‐steroidal anti‐inflammatory drug (NSAID)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Pain score (continuous data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐5.43, 4.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Combined OCP versus non‐steroidal anti‐inflammatory drug (NSAID)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002120.pub4/references#CD002120-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD002120.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD002120-note-0007">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD002120-note-0014">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD002120-note-0018">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD002120-note-0013">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD002120-note-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD002120-note-0017">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD002120-note-0009">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD002120-note-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD002120-note-0019">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD002120-note-0010">Português</a> </li> <li class="section-language"> <a class="" href="ro#CD002120-note-0020">Română</a> </li> <li class="section-language"> <a class="" href="ru#CD002120-note-0008">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD002120-note-0016">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD002120-note-0015">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002120\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002120\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002120\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002120\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002120\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002120\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002120\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002120\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002120\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002120\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002120\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002120\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002120\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002120\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002120\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002120\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002120\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002120\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=qy4lqFNF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002120.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002120.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD002120.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD002120.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002120.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728828297"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002120.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728828301"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002120.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ece021d689368',t:'MTc0MDcyODgyOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 